The QualityStocks Daily Tuesday, July 12th, 2022

Today's Top 3 Investment Newsletters

MarketClub Analysis(RHE) $3.7300 +36.88%

PennyStockProphet(HSTO) $3.7600 +27.46%

ChineseWire(BHAT) $3.3100 +22.59%

The QualityStocks Daily Stock List

NuCana (NCNA)

StockMarketWatch, MarketClub Analysis, MarketBeat, QualityStocks, TraderPower, Wealth Insider Alert, TradersPro, Schaeffer's, InvestorPlace and BUYINS.NET reported earlier on NuCana (NCNA), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

NuCana PLC (NASDAQ: NCNA; FRA: NO4A) is a clinical-stage biotechnology firm which develops new treatments for treating breast, ovarian, pancreatic, biliary, hematology and colorectal cancers, which may better how chemotherapy treatments fight cancer.

The biopharmaceutical firm uses ProTide, its proprietary technology platform to manufacture cancer medications that are better tolerated by patients as well as more effective. This technology was developed by the late Dr. Christopher McGuigan at Cardiff University.

NuCana PLC was founded on January 28, 1997 by Christopher B. Wood and Hugh S. Griffith, who is its current CEO. The firm, which was formerly known as NuCana BioMed Limited, changed its name in August 2017 before launching its IPO shortly after, in September. The company’s IPO generated $115 million. NuCana PLC serves customers in the United States as well as the U.K. and has its headquarters in Edinburgh, United Kingdom.

The company, which has a license agreement, collaboration and research with University College Cardiff Consultants Ltd and Cardiff University, has two primary ProTide technology candidates; NUC-3373 and Acelarin. The firm recently begun clinical trials for these candidates, where the former is in its Phase 1 clinical trial for the treatment of advanced solid tumors while the latter is in different phases of various clinical trials to examine the candidates’ efficacy in treating metastatic pancreatic cancer, biliary cancer, platinum-resistant ovarian cancer and biliary tract cancer. NuCana PLC is also conducting a phase 1 clinical trial for NUC-7738, its candidate designed to treat hematological tumors as well as advanced solid tumors.

Cancer is among the leading causes of death in the world. Research for a cancer cure has been ongoing for decades with no luck yet. However, the clinical trials being conducted by the firm may soon bear fruit. If NuCana does succeed in finding effective alternative treatments for various cancers, not only will their research be worth a lot, so will their stocks.

NuCana (NCNA), closed Tuesday's trading session at $0.9689, up 20.645%, on 818,558 volume. The average volume for the last 3 months is 10.88M and the stock's 52-week low/high is $0.5171/$3.3197.

Cyclerion Therapeutics (CYCN)

Kiplinger Today, StocksEarning, StockMarketWatch, MarketBeat, MarketClub Analysis, QualityStocks and INO Market Report reported earlier on Cyclerion Therapeutics (CYCN), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Cyclerion Therapeutics Inc. (NASDAQ: CYCN) is a clinical stage biopharmaceutical firm that is focused on discovering, developing and commercializing therapies for orphan and severe ailments by utilizing soluble guanylate cyclase pharmacology.

The firm has its headquarters in Cambridge, Massachusetts and was incorporated in 2018, on September 6th. It operates under the health care sector under the biotech and pharma sub-industry and serves consumers in the U.S.

The company’s aim is to prepare possible next-generation sGC stimulators. These are small molecules that act with nitric oxide synergistically on sGC (soluble guanylate cyclase) to enhance the production of cGMP.

The enterprise’s product pipeline is made up of an orally administered systemic sGC stimulator dubbed Praliciguat, which is currently undergoing phase 2 clinical trials evaluating its effectiveness in treating heart failure with preserved ejection fraction and diabetic nephropathy. Other formulations include a vascular soluble guanylate cyclase stimulator which is orally administered and known as Olinciguat, which is under phase 2 studies evaluating its effectiveness in treating sickle cell disease; and a CNS-penetrant sGC stimulator dubbed CY6463 that’s undergoing phase 2 trials for treating Alzheimer’s disease with vascular pathology, stroke-like episodes, lactic acidosis and mitochondrial encephalomyopathy.

The firm recently entered into a global license agreement with Akebia Therapeutics Inc., which will allow them to focus on their objective of developing treatments for cognitive impairment, which include the firm’s CY3018 and CY6463. This move will also allow the firms to create near and long-term value, which will be beneficial to the stakeholders of both firms.

Cyclerion Therapeutics (CYCN), closed Tuesday's trading session at $0.8199, up 15.1545%, on 151,782 volume. The average volume for the last 3 months is 7.574M and the stock's 52-week low/high is $0.4613/$4.23.

Frequency Therapeutics (FREQ)

StreetInsider, MarketBeat, Trades Of The Day, QualityStocks, InvestorPlace, The Street, The Online Investor and Schaeffer's reported earlier on Frequency Therapeutics (FREQ), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Frequency Therapeutics Inc. (NASDAQ: FREQ) is a clinical-stage biopharmaceutical firm that is focused on using the human body’s biology to reverse damage or repair damage caused by various degenerative ailments.

The firm has its headquarters in Lexington, Massachusetts and was incorporated in 2014, on November 13th by Will J. McLean, Christopher Loose, David L. Lucchino and Robert S. Langer. It operates as part of the pharmaceutical and medicine manufacturing industry, under the health care sector. The firm serves consumers in the United States and has two companies in its corporate family.

The company is party to collaboration and licensing agreements with Cambridge Enterprises Ltd, the Scripps Research Institute, the Massachusetts Institute of Technology, Mass General Brigham, and Massachusetts Eye and Ear. In addition to this, it is also party to a license and collaboration agreement with Astellas Pharma Inc., which entails developing and commercializing FX322.

The enterprise’s product pipeline comprises of a formulation dubbed FX322, which is undergoing a phase 2 clinical trial evaluating its effectiveness in treating the underlying cause of sensorineural hearing loss. In addition to this, the enterprise is also involved in the development of treatments for patients with degenerative conditions like multiple sclerosis and diseases of the bone, skin, gastrointestinal tract and muscle.

The success of the company’s FX322 formulation, which has shown improvements in hearing over extended periods of time, may not only benefit patients with sensorineural hearing loss but also encourage more investments into the company, which will have a positive influence on its growth.

Frequency Therapeutics (FREQ), closed Tuesday's trading session at $2.33, up 13.6585%, on 2,618,044 volume. The average volume for the last 3 months is 3.03M and the stock's 52-week low/high is $1.00/$9.26.

AppTech Payments (APCX)

Hot Shot Stocks, OTCPicks, HotStockCafe, QualityStocks, Penny Stock Chaser, Stock Traders Chat, FeedBlitz, PennyTrader Publisher, Wise Alerts, StockEgg, StockStreetWire, Penny Invest, CoolPennyStocks, Fierce Analyst, HotOTC, OTCReporter, Penny Stock Rumble, Small Cap Firm, StockWireNews, BullRally, Stock Source, Virmmac Team, Stock Rich, Greenbackers, TopPennyStockMovers, The Penny Stock Alert, Innovative Marketing, MicrocapVoice, PennyTrader, SeriousTraders, Real Pennies, The Cervelle Group and reported earlier on AppTech Payments (APCX), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

AppTech Payments Corp (NASDAQ: APCX) is a financial technology firm that is engaged in the provision of merchant services and electronic payment processing technologies.

The firm has its headquarters in Carlsbad, California and was incorporated in 1998, on July 2nd. Prior to its name change in December 2021, the firm was known as AppTech Corp. The firm serves consumers across the globe, with a primary focus on the U.S.

The company uses its modular fintech platform to launch digital banking solutions and omni-channel payments which enable commerce experiences that boost business growth. Its proprietary and patented software offers adaptable and progressive products which are available through various synergistic offerings directly to business enterprises, banking institutions and merchants.

The enterprise specializes in e-commerce, gift and loyalty cards, automated clearing house processing and credit card processing. Its merchant services provide financial processing for businesses to accept cashless payments, including wireless payments. Its merchant services software provides integrated solutions like issuing banking authorization, payment tokenization, data encryption and merchant-specific mobile applications for frictionless mobile and digital payment acceptance. The enterprise also develops a 2-way text chat platform which allows secure SMS services, including authentication, reporting, information queries, marketing, notifications and mobile payments.

The company recently appointed new members to its senior technical leadership team and they will be responsible for setting the technical direction and strategy of its fintech platform, while ensuring it is secure, scalable and robust. This will help meet consumer needs more effectively, which will be good for the company’s growth.

AppTech Payments (APCX), closed Tuesday's trading session at $0.6686, up 13.2836%, on 188,856 volume. The average volume for the last 3 months is 154,582 and the stock's 52-week low/high is $0.4501/$20.235.

LogicMark Inc. (LGMK)

We reported earlier on LogicMark Inc. (LGMK), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

LogicMark Inc. (NASDAQ: LGMK) (FRA: 0NIA) (LON: 0KA8) is engaged in the provision of personal emergency response systems, Internet-of-Things technology and health communications devices which create a connected care platform.

The firm has its headquarters in Louisville, Kentucky and was incorporated in 2012, on February 8th by David Charles Tunnell and Gino Miguel Pereira. Prior to its name change in March 2022, the firm was known as Nxt-ID Inc. It operates as part of the security and protection services industry, under the industrials sector. The firm serves consumers around the globe.

The company’s mission is to always apply the latest technologies for improved and new personal emergency response systems to help its consumers enjoy much-deserved independence. It operates through one business segment, called the software and hardware security systems and applications. The company continues to revolutionize the personal emergency response system industry by developing a 2-way voice communication technology that’s directly connected to the medical alert pendant, which improves the quality of life of its wearers significantly.

The enterprise, which operates through its LogicMark LLC subsidiary, manufactures and distributes monitored and non-monitored personal emergency response systems which are sold via monitored security distributors/dealers, healthcare durable medical equipment distributors and the U.S. Department of Veterans Affairs.

The company’s recently announced financial results show significant increases in its revenues, with its CEO noting that they remained focused on growing its revenues and transforming into a tech firm that would build solutions for the new care economy. This is in addition to increasing its offerings by launching new on-the-go and at-home solutions, which will better need consumer needs and increase investments into the company.

LogicMark Inc. (LGMK), closed Tuesday's trading session at $1.15, off by 0.862069%, on 122,374 volume. The average volume for the last 3 months is 17.067M and the stock's 52-week low/high is $1.03/$13.90.

Applied Molecular Transport (AMTI)

MarketBeat and StreetInsider reported earlier on Applied Molecular Transport (AMTI), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Applied Molecular Transport Inc. (NASDAQ: AMTI) is a clinical-stage biopharmaceutical firm that is focused on designing and developing a pipeline of respiratory and oral biologic product candidates to treat metabolic, inflammatory, autoimmune and other illnesses.

The firm has its headquarters in South San Francisco, California and was incorporated in 2016, on November 21st by Randall J. Mrsny and Takir Mahmood. It operates as part of the biotechnology industry, under the healthcare sector. The firm serves consumers in the United States, with a primary focus on consumers in the state of California.

The company leverages its technology platform to develop biologic therapeutic modalities such as antibody fragments, antibodies, proteins, peptides and ribonucleic acid therapeutics, in patient-friendly oral dosage forms.

The enterprise’s product pipeline consists of a gastrointestinal-selective oral fusion of interleukin 22 dubbed AMT-126, which is undergoing phase 1 clinical trials testing its effectiveness in treating illnesses related to intestinal epithelium barrier function defects. It also develops a gastrointestinal selective oral fusion of rhIL-10 known as AMT-101, which is undergoing phase 2 clinical trials evaluating its efficacy in treating ulcerative colitis and associated inflammatory indications. rhIL-10 is a potent immunomodulatory cytokine that regulates immune homeostasis in gastrointestinal mucosal tissue, among other regions in the body.

The company remains focused on advancing its AMT-101 formulation, whose success and approval for use in treating ulcerative colitis and other inflammatory illnesses would not only benefit patients with such indications, but also bring in additional revenues and investments into the company.

Applied Molecular Transport (AMTI), closed Tuesday's trading session at $2.5, up 5.9322%, on 271,479 volume. The average volume for the last 3 months is 17.919M and the stock's 52-week low/high is $1.97/$43.83.

RVL Pharmaceuticals (RVLP)

MarketBeat reported earlier on RVL Pharmaceuticals (RVLP), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

RVL Pharmaceuticals PLC (NASDAQ: RVLP) (FRA: O1P) is a specialty pharmaceutical firm that is engaged in developing and commercializing pharmaceutical products for the ocular and medical aesthetics therapeutic areas.

The firm has its headquarters in Bridgewater, New Jersey and was incorporated in 1986. Prior to its name change in January 2022, the firm was known as Osomotica Pharmaceuticals Plc. It operates as part of the biotechnology industry, under the healthcare sector. The firm serves consumers around the globe.

The company is focused on addressing the underserved patient populations in the medical aesthetics and ocular therapeutic areas as well as women’s health and neurology areas in Hungary, Argentina and the United States. Its revenues consist of licensing revenue, royalty revenues and revenues from product sales.

The enterprise’s products include an oxymetazoline hydrochloride ophthalmic solution dubbed RVL-1201 or Upneeq, which has been developed for use in treating droopy/low-lying eyelids or acquired blepharoptosis in grownups. Its other products include Osmodex ANDAs, Nitrofrantoin, ConZip AG (Tramadol ER), Lorzone AG (Chlorzoxazone), prescription prenatal vitamins, Oxybutynin ER, Sodium Phenylacetate/Socium Benzoate, Hydromorphone ER, Venlafaxine ER tablets, Methylphenidate ER, OB Complete, Divigel, OS870, Arbaclofen ER and M-72. Its Arbaclofen tablets are used to treat spasticity in patients with multiple sclerosis.

The firm remains focused on expanding the number of medical aesthetic practices that have bought its Upneeq offering, which will positively influence its revenues while it tries to establish a strong foundation for Upneeq’s adoption as a piece of the non-invasive facial aesthetics category. The continued and growing use of this product will also help extend its consumer reach, which will be good for investments.

RVL Pharmaceuticals (RVLP), closed Tuesday's trading session at $1.38, up 0.729927%, on 64,499 volume. The average volume for the last 3 months is 7.361M and the stock's 52-week low/high is $0.9801/$4.38.

Transphorm Inc. (TGAN)

QualityStocks and MarketBeat reported earlier on Transphorm Inc. (TGAN), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Transphorm Inc. (NASDAQ: TGAN) is an international semiconductor firm that is focused on the development, manufacture and sale of GaN (gallium nitride) semiconductor components to be used in power conversion.

The firm has its headquarters in Goleta, California and was incorporated in 2007 by Primit A. Parikh and Umesh K. Mishra. It operates as part of the semiconductor equipment and materials industry, under the technology sector. The firm serves consumers around the world, with a primary focus on consumers in Europe, South Korea, Japan, the United States, Taiwan, Hong Kong and Mainland China.

The company is dedicated to supporting and educating customers on the development of high voltage GaN. Its objective is to lead the GaN revolution with the highest reliability and the highest performance GaN devices for high voltage power conversion applications. The company’s innovations are moving power electronics beyond silicon’s limitations to achieve higher efficiency and more power density at a lower cost.

The enterprise’s products include GaN field effect transistors in a range of packages. Its devices enable consumers to build power systems that create functional value in various end products, which include chargers, converters, and inverters for electric cars, industrial power converters, power supplies for datacenter servers/communication and smartphone power adapters/fast-chargers, among other applications. The enterprise provides its products through sales representatives and regional distributors.

The firm recently announced its latest financial and operational results, with its CEO noting that they remained focused on delivering strong revenue growth, increasing the demand for its GaN solutions and expanding its manufacturing capacity. This will positively influence investments into the firm and help create shareholder value.

Transphorm Inc. (TGAN), closed Tuesday's trading session at $4.03, up 1.2563%, on 57,545 volume. The average volume for the last 3 months is 145,962 and the stock's 52-week low/high is $3.26/$9.14.

WaveDancer Inc. (WAVD)

InvestorPlace reported earlier on WaveDancer Inc. (WAVD), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

WaveDancer Inc. (NASDAQ: WAVD) is focused on developing and maintaining information technology systems and providing consulting as well as other IT-related professional services to commercial and government organizations.

The firm has its headquarters in Fairfax, Virginia and was incorporated in 1979 by Sandor Rosenberg. Prior to its name change in December 2021, the firm was known as Information Analysis Inc. It operates as part of the software and tech services industry, under the technology sector. The firm serves consumers around the globe.

The company specializes in legacy systems modernization, enterprise application integration, system migration and re-hosting services, enterprise portals and e-business solutions. It deploys its technologies to be used in organizations to manage very complex supply chain challenges. Its clients use the company’s platform to gain unprecedented levels of predictability, auditability and accountability from their data, while giving insights to their suppliers and partners through an immutable distributed and controlled ledger that can be trusted by all parties.

The enterprise provides cybersecurity services, cloud-based solutions, system modernizations, software development services as well as supply chain management software solutions. It also produces and markets computer applications software systems, programming services and associated software products and automation systems.

The firm, which recently announced its latest financial results, remains focused on prioritizing investments in key operational areas and entering into a definitive acquisition agreement which will allow it to become a major player in the blockchain and secure supply chain market. This will help create significant shareholder value and bolster its growth.

WaveDancer Inc. (WAVD), closed Tuesday's trading session at $1.13, off by 11.7188%, on 104,108 volume. The average volume for the last 3 months is 26,321 and the stock's 52-week low/high is $1.10/$6.00.

Newmont Corporation (NEM)

MarketClub Analysis, InvestorPlace, The Street, Schaeffer's, Kiplinger Today, StocksEarning, Market Report, The Online Investor, Barchart, MarketBeat, StreetAuthority Daily, Daily Trade Alert, TopStockAnalysts, StreetInsider, Louis Navellier, Top Pros' Top Picks, Streetwise Reports, Daily Wealth, SmarTrend Newsletters, Zacks, Money Morning, TradingMarkets, Uncommon Wisdom,, PROFIT CONFIDENTIAL, Trades Of The Day, Wealth Daily, The Growth Stock Wire, TheStockAdvisor, The Wealth Report,, ProfitableTrading, Investopedia, Wall Street Grand, Cabot Wealth, Investing Signal, The Best Newsletters, TheStockAdvisors, Market Intelligence Center Alert, Dividend Opportunities, Trading Markets, All about trends, National Inflation Association, Market FN, InvestmentHouse, Wyatt Investment Research, Energy and Capital, Money and Markets, AllPennyStocks, Stockhouse, Darwin Investing Network, Daily Markets, QualityStocks, Wall Street Daily, InvestorsObserver Team, Street Insider, Buttonwood Research, TradingAuthority Daily, OTC Stock Pick, Investiv, Wall Street Greek, Investors Alley, The Tycoon Report, StreetAlerts, Dynamic Wealth Report, MarketWatch, StockTwits, 24/7 Trader, Trading Concepts, Trader Jack, Investing Futures, FNNO Newsletters, Market Authority, Short Term Wealth, Investment House, Investment U, Daily Profit, The Stock Enthusiast, Wealth Insider Alert, and Penny Stock Buzz reported earlier on Newmont Corporation (NEM), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Gold has always been a safe haven asset for investors looking to retain the value of their money during times of market turmoil. However, gold prices have been down for quite a while and recently hit a six-month low as the U.S. dollar rallied and reached a two-decade high.

Spot gold fell by 1.4% to trade at $1,738.99 per ounce while U.S. gold futures were down by 1.5% to $1,738.3. Gold’s appeal as a safe haven asset, which may have diminished slightly due to the volatile markets, may also take a hit as the Federal Reserve adopts more restrictive monetary policies in an effort to stall inflation.

During their recent June meeting, Federal Reserve officials said that there was a high likelihood of the Fed increasing interest rates by 50 or 70 basis points during the July meeting. According to officials, elevated inflation pressures could force the Fed to take more restrictive measures, even if it means slowing the already-struggling economy.

Suki Cooper, an analyst from Standard Chartered, notes that gold has yielded to risk-off sentiment, while the U.S. dollar surged. Risk sentiment refers to how investors and traders in the financial markets are feeling and behaving. In a risk-off environment, prices of safe-haven assets increase as investors buy up bonds and gold.

The Fed’s increasingly hawkish stand against inflation will raise the opportunity costs of holding gold bullion and reduce interest.

New York-based independent metals trader Tai Wong says that the metal markets were not offered any relief from the Federal Reserve’s restrictive stance. He said that while gold may rally in the short term if payrolls are soft, the metal will need a softer U.S. consumer price index reading this week.

Such a reading would prevent the Fed from taking an even more restrictive stance and impact the metal markets. With the global economy currently in turmoil, inflation pressures may not be abating any time soon.

Factors such as rising energy prices, goods shortages, rising shipping costs, wages, trade barriers and the end of COVID-19 pandemic support significantly increased the cost of living in America and accelerated fears of impending economic inflation.  During last month’s meeting, the Fed stated that it raised benchmark borrowing rates by three-quarters a percentage point to forestall this historic rise in the cost of living. Furthermore, officials stated that they would continue to raise borrowing rates until inflation was down to 2%.

These periodic fluctuations in the price of gold on the world market are unlikely to dent the operations and plans of leading extraction companies such as Newmont Corporation (NYSE: NEM) (TSX: NGT) since they are resilient enough to ride out any short-term dips in the market.

Newmont Corporation (NEM), closed Tuesday's trading session at $57.94, off by 1.4458%, on 4,886,442 volume. The average volume for the last 3 months is 362,172 and the stock's 52-week low/high is $52.60/$86.37.

Workhorse Group Inc. (WKHS)

Green Car Stocks, InvestorPlace, MarketClub Analysis, Schaeffer's, Kiplinger Today, QualityStocks, MarketBeat, StockMarketWatch, StreetInsider, StocksEarning, TradersPro, The Street, Trades Of The Day, Daily Trade Alert, TopPennyStockMovers, TraderPower, BUYINS.NET, Zacks, Wealth Insider Alert, Early Bird, Jason Bond, Cabot Wealth, InvestorsUnderground, PoliticsAndMyPortfolio, StockOodles, The Online Investor,, Profitable Trader Authority, Stock Beast, Wealth Daily, Energy and Capital, The Best Newsletters, Daily Market Beat and The Wealth Report reported earlier on Workhorse Group Inc. (WKHS), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Electric vehicles are said to be the next stage in vehicular transportation. However, they are very costly, require charging infrastructure that simply isn’t there yet and are currently battling with a crippling global shortage of semiconductor chips. But despite these mitigating factors, EV makers managed to sell a record number of electric cars in May, indicating that the nascent EV space is still going strong.

Global electric vehicle sales reached almost 700,000 in May, increasing by a whopping 55% amid economic woes and supply chain constraints. Data from EV-Volumes shows that customers registered 699,708 passenger electric cars in May, raising the market share of electric cars to around 12%. Battery electric vehicles (BEV) made up 8.6% of the market share and plug-in hybrid electric vehicles (PHEVs) had a 3.4% share.

The data reveals an interesting fact: while BEV sales are much higher than plug-in hybrid sales and have increased a lot faster, sales of nonrechargeable hybrids have slumped for the second month in a row. BEV sales saw a 65% year-on-year increase to around 501,000, and PHEV sales were up by 37% to 198,000.

Over the past six months, drivers around the world registered more than 3.2 million new passenger plug-in EVs compared to nearly 6.5 million over the entirety of 2021. Battery electric vehicles were the majority with around 2.39 million in sales and an 8.1% market share while PHEVs saw about 0.85 million units in sales and a 2.9% share. If May’s trend continues, EV makers may be able to surpass their 2021 sales by the end of the year.

The Wuling Hong Guang MINI EV was the top-selling electric vehicle in May with 34,037 units sold. Developed by Chinese manufacturer Wuling Motors, the mini EV costs just $5,000 and has seen significant sales in the Chinese market, even outselling Tesla. Wuling is now looking to capitalize on the success of the Mini EV by developing different versions, including a forthcoming “long-range” version.

It was closely followed by the BYD Song (31,989), Tesla Model Y (28,147), BYD Han (23,978), Tesla Model 3 (22,621), BYD Qin Plus (17,974), BYD Yuan Plus (11,550), Li Xiang One EREV (11,496), Volkswagen ID.4 (10,728,), and the GAC Aion S (10,504).

Chinese automaker BYD recorded the highest number of plug-in EV registrations in May at 114,993 followed by Tesla (57,472), SAIC-GM-Wuling (38,045), SAIC (28,660), Volkswagen (26,921) and BMW (26,408).

These statistics suggest that the future is indeed rosy for EV sector actors such as Workhorse Group Inc. (NASDAQ: WKHS) as electric vehicle adoption accelerates around the world.

Workhorse Group Inc. (WKHS), closed Tuesday's trading session at $2.75, up 0.364964%, on 3,590,184 volume. The average volume for the last 3 months is 105,546 and the stock's 52-week low/high is $2.11/$13.09.

BIT Mining Limited (BTCM)

MarketClub Analysis, QualityStocks, Schaeffer's and StocksEarning reported earlier on BIT Mining Limited (BTCM), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

BIT Mining (NYSE: BTCM), a leading technology-driven cryptocurrency mining company, today announced its entry into a share sale and purchase agreement with an unaffiliated third party (the “buyer”). Under the agreement, the company agreed to sell and the buyer agreed to purchase approximately 51% of the total issued share capital of Loto Interactive Limited, representing 279,673,200 shares of Loto Interactive, each at the price of HK$0.28, for the total consideration of HK$78,308,496 (the “transaction”). Upon closing of the transaction, the company’s share ownership in Loto Interactive will decrease to 8.79%. “Following our strategy to focus on developing in the U.S., we believe this is the right decision to sell a majority of our shares of Loto Interactive and devote our resources more extensively to the North American market,” said Xianfeng Yang, CEO of BIT Mining. “Going forward, with the North American market as our center of excellence, we will continue to invest in technology, innovation and high-quality mining resources worldwide. At the same time, we will constantly improve operational efficiency as we expand our business to build a strong foundation across the cryptocurrency ecosystem.”

To view the full press release, visit

About BIT Mining Limited

BIT Mining is a leading technology-driven cryptocurrency mining company with a long-term strategy to create value across the cryptocurrency industry. Its business covers cryptocurrency mining, mining pool and data center operation. The company owns the world’s top blockchain browser and the comprehensive mining pool business operated under, providing multi-currency mining services including BTC, ETH and LTC. The company also owns a 7-nanometer cryptocurrency mining machine manufacturer, Bee Computing, completing the company’s vertical integration with its supply chain, increasing its self-sufficiency and strengthening its competitive position.

BIT Mining Limited (BTCM), closed Tuesday's trading session at $0.6591, off by 7.169%, on 947,342 volume. The average volume for the last 3 months is 915,879 and the stock's 52-week low/high is $0.60/$14.65.

The QualityStocks Company Corner

Lexaria Bioscience Corp. (NASDAQ: LEXX)

The QualityStocks Daily Newsletter would like to spotlight Lexaria Bioscience Corp. (NASDAQ: LEXX).

  • Lexaria is a global innovator in drug delivery platforms
  • The company has developed the patented DehydraTECH(TM) technology that significantly improves the bioavailability of orally administered pharmaceuticals and therapeutics
  • Bioavailability is the fraction of a drug that reaches the site of action or systemic circulation
  • While drugs delivered intravenously are 100% bioavailable, drugs that have any other route of administration, such as oral, have reduced bioavailability
  • DehydraTECH enhances the bioavailability of APIs, in part, by bypassing first-pass liver processing

Global innovator Lexaria Bioscience (NASDAQ: LEXX) has built a reputation as a developer of drug delivery platforms, the most notable of which is the patented DehydraTECH(TM) technology. DehydraTECH is a formulation and dehydration processing method that modifies how the body detects and absorbs drugs, solving a glaring problem that has long affected orally administered drugs: low bioavailability. 

Lexaria Bioscience Corp. (NASDAQ: LEXX) is a global innovator in drug delivery platforms. The company’s patented technology, DehydraTECH™, improves the way active pharmaceutical ingredients (APIs) enter the bloodstream by promoting healthier oral ingestion methods and increasing the effectiveness of fat-soluble active molecules. DehydraTECH promotes fast-acting, less expensive and more effective oral drug delivery and has been thoroughly evaluated through in vivo, in vitro and human clinical testing.

DehydraTECH is covered by 21 issued and more than 50 pending patents in over 40 countries around the world. Lexaria’s first patent was issued by the U.S. Patent and Trademark Office in October 2016 (US 9,474,725 B1), providing 20 years of patent protection expiring June 2034. Multiple patents have been awarded since then and are expected in the future.

Lexaria has a collaborative research agreement with the National Research Council (NRC), the Canadian government’s premier research and technology organization. The company has filed for patent protection for specific delivery of nicotine, vitamins, NSAIDs, testosterone, estrogen, cannabinoids, terpenes, PDE5 inhibitors (with brand names like Viagra), tobacco and more.

Lexaria began developing DehydraTECH in 2014 and has since continued to strengthen and broaden the technology. The company has no plans to create or sell Lexaria-branded products containing controlled substances. Instead, Lexaria licenses its technology to other companies around the world to offer consumers the best possible performance across an array of ingestible product formats.

The company’s technology is best thought of as an additional layer that providers of consumer supplements, prescription and non-prescription drugs, nicotine and CBD products can utilize to improve the effectiveness of their own existing or planned new offerings. Lexaria has licensed DehydraTECH to multiple companies, including a world-leading tobacco producer for the research and development of smokeless, oral-based nicotine products, and for use in industries that produce cannabinoid beverages, edibles and oral products.

DehydraTECH is suitable for use with a wide range of product formats including pharmaceuticals, nutraceuticals, consumer packaged goods and over-the-counter capsules, pills, tablets and oral suspensions.

DehydraTECH Technology

Lexaria’s DehydraTECH is designed specifically for formulating and delivering lipophilic (fat-soluble) drugs and active ingredients. DehydraTECH increases their effectiveness and improves the way active pharmaceutical ingredients enter the bloodstream. The major benefits to a subject ingesting a DehydraTECH-enabled drug or consumer product can be summarized by the following:

  • Speeds up delivery – the effects of the product are felt by the subject in just minutes.
  • Increases bioavailability – the technology is much more effective at delivering a drug or product into the bloodstream.
  • Increases brain absorption – animal testing suggests significant improvement in the quantity of drug delivered across the blood-brain barrier.
  • Improves drug potency – more of the ingested product is made available to the body, so lower doses are required to achieve the desired effect.
  • Reduces drug administration cost – lower doses mean lower overall drug costs.
  • Masks unwanted taste – the technology eliminates or reduces the need for sweeteners.

Lexaria has demonstrated in animal studies a propensity for DehydraTECH technology to elevate the quantity of drug delivered across the blood-brain barrier by as much as 1,900 percent, initiating additional new patent applications and opening possibilities for improved drug delivery.

Since 2016, DehydraTECH has repeatedly demonstrated, with cannabinoids and nicotine, the ability to increase bio-absorption by up to five to 10 times, reduce time of onset from one to two hours to just minutes, and mask unwanted tastes. The technology is to be further evaluated for additional orally administered bioactive molecules, including antivirals, cannabinoids, vitamins, non-steroidal anti-inflammatory drugs (NSAIDs) and nicotine.

Market Outlook

Lexaria’s ongoing research and development efforts are mainly focused on development of product candidates across several key segments:

  • Oral Cannabinoids – a market estimated to be worth $18.4 billion in 2021 and expected to reach $46.2 billion by 2025.
  • Antivirals – an estimated $52.1 billion market in 2021 that’s expected to grow to $66.7 billion by 2025.
  • Oral Mucosal Nicotine – smokeless tobacco products, a $13.6 billion market in 2018, is forecast to grow at 7.2 percent annually through 2025.
  • Human Hormones – estrogen and testosterone replacement therapies represented a $21.9 billion market in 2019, with a forecast CAGR of 7.7 percent through 2027.
  • Ibuprofen and Naproxen – NSAID sales totaled $15.6 billion globally in 2019 and are projected to reach $24.4 billion by 2027.
  • Vitamin D3 – the global market size was $1.1 billion in 2021, growing at 7 percent per year and expected to reach $1.7 billion in 2026.

Management Team

Chris Bunka is Chairman and CEO of Lexaria Bioscience Corp. He is a serial entrepreneur who has been involved in several private and public companies since the late 1980s. He has extensive experience in the capital markets, corporate governance, mergers and acquisitions, as well as corporate finance. He is named as an inventor on multiple patent innovations.

John Docherty, M.Sc., is the President of Lexaria. He is a pharmacologist and toxicologist, and a specialist in the development of drug delivery technologies. He is the former president and COO of Helix BioPharma Corp. (TSX: HBP). He is named as an inventor on multiple issued and pending patents.

Greg Downey is Lexaria’s CFO. He has more than 35 years of diverse financial experience in the mining, oil and gas, manufacturing, and construction industries, and in the public sector. He served for eight years as CFO for several public companies and has provided business advisory and financial accounting services to many large organizations.

Gregg Smith is a strategic advisor to Lexaria. He is a founder and private investor with Evolution VC Partners. He is a member of the Sand Hill Angels and held previous investment banking roles with Cowen and Company and Bank of America Merrill Lynch.

Dr. Philip Ainslie serves as a scientific and medical advisor to Lexaria. He is co-director for the Centre for Heart, Lung and Vascular Health, Canada. He is also Research Chair in Cerebrovascular Physiology and Professor at the School of Health and Exercise Sciences, Faculty of Health and Social Development at the University of British Columbia.

Lexaria Bioscience Corp. (LEXX), closed Tuesday's trading session at $2.84, up 1.7921%, on 70,046 volume. The average volume for the last 3 months is 10,512 and the stock's 52-week low/high is $1.85/$12.50.

Recent News

Freight Technologies Inc. (NASDAQ: FRGT)

The QualityStocks Daily Newsletter would like to spotlight Freight Technologies Inc. (NASDAQ: FRGT).

Freight Technologies (NASDAQ: FRGT), a technology company developing solutions to optimize and automate the supply chain process and providing a platform for B2B cross-border shipping in the NAFTA region, announced that it has upgraded its electronic data interchange (“EDI”). The upgraded EDI now features the ability to enable location sharing and shipment status changes. “To help increase Fr8App large shippers’ efficiency and the stickiness of our application, we continue to improve our EDI, which increases notification speed and reduces costs with our agile, paperless electronic exchange of data,” said Fr8Tech and Fr8App CEO Javier Selgas in the press release. “Recently, we unveiled exciting new features which have been very well received by a number of our key shipper clients. Location sharing improvements enhance our shippers’ ability to track and trace loads, thereby helping them with making their operations more efficient. Shipment status features automatically update the shippers’ systems about the load delivery process. Driven to continually meet the evolving needs of our customers, Fr8App is dedicated to lead technology in supply chain management and cross-border shipping.” To view the full press release, visit

Freight Technologies Inc. (NASDAQ: FRGT) (“Fr8Tech”) is a technology company developing solutions to optimize and automate the supply chain process, providing a platform for B2B cross-border shipping in the NAFTA region. The company’s mission is to revolutionize cross-border shipping by providing carriers with increased growth opportunities and shippers with flexibility, visibility and simplicity for the once-complex process of international over-the-road shipping.

Freight Technologies, formerly known as Hudson Capital Inc., assumed its current name and ticker symbol on May 27, 2022. Its primary operating subsidiary and its marketplace are known as Fr8App, and it conducts operations throughout North America under the names of Fr8App and/or Freight App. The company is headquartered in Houston, Texas, with multiple locations across the U.S. and Mexico.

The Fr8Tech Solutions Suite

Fr8Tech leverages artificial intelligence to provide cloud-based platforms aimed at automating the over-the-road transportation process, effectively reducing human touch points and expediting load booking times. The company’s suite of solutions includes:

  • Fr8app – A B2B marketplace powered by AI and Machine Learning offering a real-time broker portal to connect shippers with qualified carriers
  • Fr8Radar – A tracking solution providing shippers and carriers real-time locational data via Fr8app’s mobile solution or through integration with third-party GPS alternatives
  • Fr8TMS – A transportation management system designed to help shippers manage their freight and all of the documents involved in shipping transactions, including invoices, customs documents, confirmation rates and proof of deliveries
  • Fr8FMS – A fleet management system allowing transportation companies to better manage their fleets, reduce operational costs and provide better service to their customers
  • Fr8Data – A data solution offering real-time dashboards and reports to shippers and carriers in an effort to increase visibility and control while supporting better business decisions
  • Fr8Fleet – A platform that provides private fleet management, enabling large corporate shippers to purchase dedicated capacity secured by Fr8app in exchange for a fixed fee

Commitment to the Environment

Through its core focus on technology, Fr8Tech seeks to reduce the carbon footprint of the logistics industry. Its solutions aim to minimize empty miles for transportation firms and reduce overall paper consumption.


Fr8University is an educational program offering classroom and on-the-job training for Fr8Tech team members. Through the program, employees learn in-depth business fundamentals and applications along the truckload freight industry value chain.

Led by corporate educator Mario Mena, Fr8University is designed as an investment in the company’s human capital, providing an opportunity to communicate Fr8Tech’s corporate culture while accelerating operational growth.

Market Outlook

Fr8Tech’s established foothold in Mexico is key to its current efforts to promote sustainable growth in the cross-border shipping industry. Ongoing disruption in U.S.-Chinese trade relations have strengthened Mexico’s status as the largest trading partner of the U.S., with cross-border annual freight spending estimated at $385 billion according to data from the U.S. Department of Transportation. Annual domestic shipping in Mexico is estimated at $34 billion, while annual domestic shipping in the U.S. is estimated to total $732 billion.

Despite the size of this industry, fragmentation and inefficiencies prevail in the space. Thousands of legacy brokers, tens of thousands of shippers and hundreds of thousands of carriers still rely on outdated systems to arrange transport, spending hours on the phone negotiating pricing, waiting days to find trucks and drivers, preparing and printing forms, and operating without tracking or visibility. Add in cross-border complexity relating to customs and additional paperwork, and you have an industry ripe for technological disruption.

Fr8Tech’s recent revenue growth trends have highlighted the company’s efforts to capitalize on this opportunity. In 2021, Fr8Tech achieved revenues of $21.5 million, marking a year-over-year increase of 134%. The company issued revenue guidance for fiscal 2022 of $40 million in a February 9, 2022, press release, which would account for a further 86% year-over-year increase.

Management Team

Javier Selgas is CEO and a Director of Freight Technologies Inc. and Freight App Inc. He brings to the company over 15 years of experience developing technology and digital marketing strategies, including serving as Country Manager for Osigu, Spain, and as head of AJEgroup’s IT division for the Asia-Pacific region. Prior to joining Fr8Tech, Mr. Selgas founded digital marketing agency Lanzadera Online. He has also served as an IT consultant to major corporations, including Endesa and Ibermatica.

Mike Flinker is President of Fr8Tech. He has over four decades of experience in the transportation industry, with 30+ years focused on cross-border logistics. Prior to joining Fr8Tech, Mr. Flinker founded FLS Transportation, the largest cross-border logistics company in Canada. He also previously held positions with Clarke Transport Inc., Canadian Pacific and Reimer Express Inc. (a division of Roadway Express).

Paul Freudenthaler is the company’s CFO and Secretary to the company Board. He has over 30 years of financial expertise, having previously served as CFO for several leading companies across multiple countries, including Macquarie in Mexico, Old Mutual in Latin America and Ascentium Capital in the U.S. Mr. Freudenthaler’s experience include leadership roles from which he guided IPOs and M&A transactions.

Luisa Lopez is COO of Fr8Tech. She brings to the company 25+ years of management experience in logistics, supply chain, operations and customer service. Ms. Lopez previously served as a Director of Landstar, where she was responsible for commercial and client development strategies in the Mexican market. Additionally, she managed more than 2,000 transport units specialized in staff and school mobility while with Traxion in Mexico.

Freight Technologies Inc. (NASDAQ: FRGT), closed Tuesday's trading session at $1.48, up 7.2464%, on 10,525 volume. The average volume for the last 3 months is 46.71M and the stock's 52-week low/high is $1.28/$9.90.

Recent News

Silo Pharma Inc. (OTCQB: SILO)

The QualityStocks Daily Newsletter would like to spotlight Silo Pharma Inc. (OTCQB: SILO).

Silo Pharma (OTCQB: SILO), a development-stage biopharmaceutical company, today announced that its novel liposomes reached a positive endpoint in animal studies showing effectiveness and reduced toxicity using a subcutaneous delivery method. “The successful results of our study show that the subcutaneous route of liposomal administration is well-suited for use in targeted drug delivery of anti-arthritic agents. We suggest that this drug delivery approach would not only enhance efficacy but also reduce systemic toxicity,” said Eric Weisblum, CEO of Silo Pharma. “In our previous work, ART-1-Cy7-liposomes injected i.v. demonstrated homing to arthritic joints and four hours was an optimal time point for high fluorescence intensity in the hind paws. The results of this new study show that the time kinetics and quantitative aspects of liposomes administered subcutaneous were not much different from that of liposomes injected i.v. In fact, despite some initial delay, the signal strength showed a trend towards a higher level in subcutaneous than in i.v.” To view the full press release, visit In January, the Drug Enforcement Administration announced a proposed ban on five psychedelics: 4-OH-DiPT, 5-MeO-AMT, 5-MeO-MiPT, 5-MeO-DET and DiPT. With the country going through what some have called a psychedelics renaissance, the agency received significant criticism for its proposed decision. As such, the DEA stated in a recent notice that it will be holding a hearing on Aug. 22, 2022, to listen to testimonies from individuals who were “adversely aggrieved or affected” by its proposed ban. It is highly like that leading psychedelics industry actors such as Silo Pharma Inc. (OTCQB: SILO) will in one way or the other share their input about the planned ban. It will then be up to the DEA to act upon or ignore the feedback it receives during the upcoming hearing.

Silo Pharma Inc. (OTCQB: SILO), a developmental stage biopharmaceutical company, is focused on merging traditional therapeutics with psychedelic research for people suffering from indications such as post-traumatic stress disorder (PTSD), fibromyalgia, Alzheimer’s disease, Parkinson’s disease, and other rare neurological disorders. Silo’s mission is to identify assets to license and fund research that the company believes will be transformative to the wellbeing of patients and the health care industry.

Silo is committed to developing innovative solutions to address a variety of underserved conditions. Combining Silo’s resources with world-class medical research partners, the company looks to make significant advances in the medical and psychedelic space.

Silo works to identify and partner with leading medical universities, providing the needed financial resources to develop safe therapeutic treatments while moving cutting-edge research through the clinical stage and into commercialization. The company is well-capitalized with access to additional funds as opportunities present themselves.

Silo recently engaged Donohoe Advisory Associates LLC for consulting and advisory services in connection with the potential uplisting of Silo’s common shares to the Nasdaq Stock Market.


Silo has entered into research agreements and partnerships with multiple leading medical universities.

The company is involved in a sponsored study with Maastricht University utilizing repeated low doses of ketamine and psilocybin to examine the effects on cognitive and emotional dysfunctions in Parkinson’s disease and to understand its mechanism of action. The investigator in the Netherlands is acquiring the substances for the study and will then finalize the documentation to submit to the ethics committee.

Additionally, in June 2021, Silo announced its entry into a scientific research agreement with the University of California San Francisco (UCSF). The agreement will leverage four other clinical trials being planned by the university to determine the effects of psilocybin on inflammation. The study will take place at The Translational Psychedelic Research (TrPR) Program at UCSF.

Silo also recently extended its exclusive option agreement with the University of Maryland, Baltimore (UMB) to explore a novel invention generally known as joint-homing peptides. These peptides are being developed for use in the investigation and treatment of arthritogenic processes and can be used for enhanced targeting of therapeutic agents.

This agreement includes the study of two separate peptides. The first is an option and study for the treatment of arthritis. The second is a patented licensed peptide for the central nervous system, with an initial study for MS autoimmune diseases, in addition to rheumatoid arthritis. Animal studies are underway for both initial indications relating to the UMB agreement, with the potential for studies evaluating additional indications in the future.

Finally, Silo signed an agreement with Columbia University granting it an option to license certain assets currently under development, including an Alzheimer’s disease formulation targeting NDMARs and 5-HT4Rs, as well as a prophylactic treatment for stress-induced disorders and PTSD. Both candidates are currently being tested in mice and have already provided early data.

In addition to its university partnerships, Silo entered a joint venture agreement with Zylo Therapeutics Inc. (“ZTI”) focused on the development of ketamine and psilocybin using ZTI’s Z-Pod™ technology for the transdermal time released delivery of therapeutics. In November 2021, the company announced ZTI’s reception of its first ketamine shipment and initiation of loading ketamine into its Z-Pod technology. In a news release, Eric Weisblum, CEO of Silo, called the development an “important milestone” that will help the company “study the benefits of slow-release transdermal release of Ketamine.”

Market Overview

According to Coherent Market Insights, the fibromyalgia treatment market was valued at $2.78 billion in 2018 and has a projected CAGR of 3.3% over the forecast period 2018 to 2026. Fibromyalgia is a condition that causes pain all over the body, sleep problems, fatigue, and emotional and mental distress.

The global PTSD therapeutics market is expected to reach $10.68 billion by 2026 with a CAGR of 4.5% during the forecast period from 2018 to 2026, according to a report by Credence Research. Growing prevalence of PTSD is the chief factor driving the global treatment market. Increases in events such as wars, combat, and interpersonal violence has been a major contributing factor. Other factors like growing emphasis on rehabilitation initiatives by governments for treating their war veterans has also been facilitating the increase in demand for PTSD therapeutics.

Fortune Business Insights reports the global Parkinson’s disease treatment market is predicted to grow to $8.38 billion by 2026, with a CAGR of 8.1% during the forecast period. Parkinson’s is a neurodegenerative disease of the central nervous system which primarily affects the brain, causing uncontrollable shaking and tremors, difficulties in balance and restricted body movement making it difficult for the person to function or perform a daily routine.

Management Team

Eric Weisblum is CEO and founder of Silo Pharma. He has over 25 years of Wall Street experience, most recently in the biotechnology sector. He has served on the board of Aikido Pharma and was the president of Sableridge Capital. He has a proven track record in licensing therapeutic assets and assisting in their development. He brings to the company nearly 20 years of expertise in structuring and trading financial instruments. He holds a bachelor’s degree from the University of Hartford’s Barney School of Business.

Dr. Kevin Muñoz was appointed to the Silo board of directors in October 2020. He teaches biomedical sciences and medical intervention for the Passaic County Technical Institute. He previously served as Director of Operations at Physical Medicine and Rehabilitation. He began his career with Harlem Health Promotion Center in New York City as a research assistant. He earned a bachelor’s degree from the University of Michigan and a Doctor of Medicine from Xavier University School of Medicine.

Josh Woolley, M.D., Ph.D., is a Scientific Advisor for Silo. He is an associate professor in the Department of Psychiatry and Behavioral Sciences at the University of California, San Francisco. He is also a psychiatrist on staff at the San Francisco Veterans Affairs Medical Center. He is the director and founder of the Bonding and Attunement in Neuropsychiatric Disorders Laboratory. He received both his M.D. and his Ph.D. in Neuroscience from UCSF, where he completed his psychiatry residency training.

Charles Nemeroff, M.D., Ph.D., is a Scientific Advisor for Silo Pharma. He directs the Institute for Early Life Adversity Research within the Department of Psychiatry and Behavioral Sciences as part of the Mulva Clinic for the Neurosciences. He was chair of the Department of Psychiatry and Behavioral Sciences and clinical director of the Center on Aging at the University of Miami Miller School of Medicine. He received his M.D. and Ph.D. in neurobiology from the University of North Carolina School of Medicine.

Silo Pharma Inc. (OTCQB: SILO), closed Tuesday's trading session at $0.1149, up 14.9%, on 57,360 volume. The average volume for the last 3 months is 7,195 and the stock's 52-week low/high is $0.0892/$0.2489.

Recent News

Correlate Infrastructure Partners Inc. (OTCQB: CIPI)

The QualityStocks Daily Newsletter would like to spotlight Correlate Infrastructure Partners Inc. (OTCQB: CIPI).

  • Clean energy investment has posted a 12% YOY growth since 2020, with global energy investment set to reach $2.4 trillion in 2022
  • Renewable electricity capacity is projected to rise by over 60% by 2026, achieving 4,800 GW
  • In June 2022, President Biden dropped tariffs on Southeast Asian solar panel imports for 24 months to accelerate clean energy product development in the country
  • CIPI stands to benefit significantly from the increasing push to adopt clean energy 

The International Energy Agency’s (“IEA”) World Energy Investment 2022 report, released in late June, noted that the global energy investment was set to reach $2.4 trillion in 2022, representing an 8% increase from 2020. Moreover, the report noted that since 2020, clean energy investment had grown significantly, posting a 12% year-over-year (“YOY”) growth, a notable increase from 2% posted within the first five years following the Paris Agreement in 2015 ( One company that stands to benefit from this is Correlate Infrastructure Partners (OTCQB: CIPI). Known for offering a complete suite of proprietary clean energy assessment and fulfillment solutions for commercial real estate, this company understands the value of scaling distributed clean energy solutions. It believes this is critical in mitigating the effects of climate change while allowing enterprise clients to monetize this new cash flow opportunity for growth.

Correlate Infrastructure Partners Inc. (OTCQB: CIPI), formerly Triccar Inc., through its two subsidiaries, Correlate and Solar Site Design, offers a complete suite of proprietary clean energy assessment and fulfilment solutions for the commercial real estate industry. The company believes scaling distributed clean energy solutions is critical in mitigating the effects of climate change. CIPI is at the forefront in creating an industry-leading energy solution and financing platform for the commercial and industrial sector. The company sees tremendous market opportunity in reducing site-specific energy consumption and deploying clean energy generation and energy efficiency solutions at scale.

The opportunity exists to remove friction between today’s legacy finance process and the needed clean-energy upgrades developed within the company’s program technologies. For the U.S. to reach its 2050 carbon goals, 200,000 commercial buildings must be retrofitted every year until that date. That represents approximately a 5-10x increase over the 2022 industry process run rate.

CIPI announced completion of its acquisition of 100% of the equity of Correlate Inc. and Loyal Enterprises LLC dba Solar Site Design on December 28, 2021. The company notes these acquisitions occurred at a key inflection point of its growth. CIPI currently enjoys channel and sales partnerships with Fortune 250 companies and a strong, proven industry network.

The company’s transparent, leading-edge model changes value delivery for both facility owners and proven solution providers seeking scale. CIPI believes its rapid growth is due to industry demand for actionable, cashflow positive energy programs and the underlying carbon reduction mandates taking effect globally.

CIPI has filed with the SEC for a name change to Correlate Infrastructure Partners Inc., which will more closely reflect its new platform and growth focus. The company has been aggressively moving to rebrand, with efforts including a revised website, investor presentation materials and an investor relations awareness campaign. The company’s shares will continue to trade on the OTCQB Venture Market under the current ‘CIPI’ ticker symbol until changes are approved.


Correlate, founded in 2015, is a portfolio-scale development and finance platform offering commercial and industrial facilities access to clean electrification solutions focused on locally-sited solar, energy storage, EV infrastructure, and intelligent efficiency measures. Its unique data-driven approach is powered by proprietary analytics, concierge subscription services, and a highly scalable national fulfillment network to help building owners profit from fully funded, turnkey decarbonization and facility health programs. The platform is designed for commercial and industrial real estate owners seeking to significantly improve net operating income while meeting carbon reduction goals. The platform provides energy programs for commercial property portfolios and requires no upfront capital. Client organizations reduce their risk and generate more profits by leveraging Correlate’s unique payment programs to put more cash in the bank. Deploying Correlate’s strategic energy programs and energy management systems allows property-owning organizations to complete big energy changes across their portfolios.

Solar Site Design, founded in 2013, is a U.S. Department of Energy Sunshot Catalyst winner that provides customer acquisition and project development tools for the commercial solar industry. Its commercial marketplace platform connects highly qualified project opportunities to leading solar construction companies nationwide. The Solar Site Design platform gives commercial and industrial property owners access to the best price for a commercial solar system. Commercial solar analysts provide property owners a site assessment and working project proposal. Solar Site Design’s team of solar engineers finalize the design while approved financing providers help clients explore financing options for their projects. Then, approved contractors in Solar Site Design’s Marketplace bid on the projects, ensuring commercial and industrial property owners get the best estimates for their projects. Solar Site Design’s marketplace process promotes transparency and fair pricing. Its team of experts has nearly 20 years of experience in the solar industry. Only reputable, experienced, certified (NABCEP), licensed, bonded and insured contractors are accepted into the Solar Site Design Marketplace.

Market Outlook

CIPI is in a rapidly growing market with a unique offering to address a total market of more than 5.9 million commercial buildings in the United States, according to the U.S. Energy Information Administration. Currently, the company’s wholly owned subsidiaries, Correlate and the Solar Site Design, have an opportunity pipeline of over $100 million in commercial projects with more than $20 million in awarded backlog. According to the Rocky Mountain Institute, portfolio energy optimization is a $290 billion market in the United States driving deep financial savings and energy efficiency across the commercial sector.

Commercial buildings consume more than 35% of the generated electricity in the U.S. and are underperforming in energy efficiency at every level. These buildings waste energy, emit too much carbon, and are too costly for owners and occupants, but retrofits are not happening at the rate or scale needed.

In today’s real estate market, portfolio property owners own most commercial buildings. Yet most building efficiency work is focused on single buildings, thereby missing the distinct needs of this owner class which has very different needs than traditional owner-occupiers. The diverse nature of commercial buildings, combined with technology and performance uncertainty, make simple energy optimization initiatives – which could greatly reduce energy use and improve building value – financially unattractive, resulting in slow adoption rates. CIPI’s financial instruments and software breakdown this issue known as the “split incentive”, unlocking the majority of the addressable market.

Management Team

CIPI has in place a nationally recognized management team that has been active in the energy market since 2005.

Todd Michaels is President and CEO of CIPI and founder of Correlate. He formerly served as Vice President for Innovation at SunEdison and Senior Director Distributed Solar at NRG Energy. He founded Correlate in 2015 and has 16 years of experience in the energy industry. He graduated from Indiana University with a B.S. in Computer Information Systems.

Channing Chen is CFO at CIPI and Correlate Inc. and brings over 16 years of experience in the solar industry as a developer, financier, and business unit leader. He has held executive management roles at Solar Power Partners (acquired by NRG Energy), where he was a founding employee, SunEdison, and NRG Energy (NYSE: NRG). Most recently, Mr. Chen was founder and Managing Partner at Breakaway Energy Partners LLC – a distributed energy financing and market-making platform. To date, Mr. Chen and his teams have raised over $1.5 billion in financing across residential, commercial, and utility scale solar and energy storage projects representing over 400 MWs. He holds a B.A. in Environmental Chemistry from the University of California at San Diego and an MBA from the University of Southern California. He is also an advisor and early-stage investor to several startup companies in the renewable energy space.

David Bailey is Chief Revenue Officer of Correlate Inc. With over 15 years of executive sales, supply chain management, and energy efficiency experience, he is responsible for ensuring the success of the National Commercial Sales Unit across multiple regional project teams. Mr. Bailey created and launched the Transformation Services team while at Wesco for its multibillion-dollar Distributed Energy Resource division, formerly Westinghouse. His focus was on IoT-enabled efficiency and plant floor automation-based services. Before that, he spent several years in Global Account Sales Management, with GE Supply as a Program Manager, and is a Commercial Leadership Program graduate. Mr. Bailey received his B.S. in Mechanical Engineering from the University of Kentucky.

Jason Loyet is VP of Commercial Sales of Correlate Inc. He is a cleantech executive with over 20 years of experience leading high growth solar energy and software start-ups. Mr. Loyet is a U.S. Department of Energy SunShot Catalyst award winner for his work building the Solar Site Design technology platform. Before joining the solar energy industry in 2005, he founded and sold two software companies in the streaming media (GlobalStreams) and newspaper publishing (MyCapture) industries. Mr. Loyet currently serves as a Member of the Board of Directors for the Tennessee Solar Energy Industry Association (TenneSEIA).

Deke Welling is Head of Project Development and Fulfillment Services at Correlate Inc. He has over 19 years’ experience in the energy industry with an emphasis on renewables and energy efficiency over the past seven years. Prior to entering the renewables sector, Mr. Welling was the CEO of Welling Resources, an energy development company focused on the exploration of oil and natural gas reserves in the U.S. It was this experience that led him into the renewables sector and leading a charge for more sustainable resources. Additionally, Mr. Welling also served as the CEO of Circle L Solar Inc., a top 100 solar installer in the United States since 2016. Through his leadership, Circle L Solar experienced a growth rate of over 2,250% from 2016 to 2019, resulting in his company being listed on the Inc. 5000 list of the fastest growing private companies in the U.S. (Rank #176) and being named ‘Top Energy Company’ and ‘Entrepreneur of Year for the Energy Industry’ by the American Business Awards® in 2019 and again for ‘Entrepreneur of the Year’ in 2021.

Kevin Warren is Head of Construction and Development Engineering at Correlate Inc. He is a solar veteran with over 12 years of experience in the field. Prior to co-founding CLS, Mr. Warren was the owner of Beacon Consulting and has originated, consulted, designed and/or engineered over 122 MW of PV installations ranging from small commercial to utility scale projects throughout Texas, California, Colorado and North Carolina. He holds a Photovoltaic Technical Sales Professional Certification from the North American Board of Certified Energy Practitioners and certifications from Solar Energy International in PV Installation, PV Technical Sales, PV battery-based design, PV design and engineering, and PV operations and maintenance. Along with PV expertise, Mr. Warren is a LEED Green Building Associate, a certified building analyst from the Building Performance Institute, a Certified Renewable Energy Professional from the Association of Energy Engineers and holds a designation in High-Performance Sustainable Buildings from the BOMI Institute. He studied Electrical Engineering at the University of Texas at Arlington.

Tom Kunhardt is Director of Customer Success at Correlate. He previously held a similar position at Clean.Tech and was Corporate Trainer, Learning & Development, at NRG Energy. He has 15 years of experience in the solar and clean energy industries helping homeowners and businesses find solutions to their energy needs. He holds a bachelor’s degree from the University of Massachusetts.

Correlate Infrastructure Partners Inc. (OTCQB: CIPI), closed Tuesday's trading session at $1.25, even for the day, on 500 volume. The average volume for the last 3 months is 1,050 and the stock's 52-week low/high is $0.30/$3.25.

Recent News

GeoSolar Technologies Inc.

The QualityStocks Daily Newsletter would like to spotlight GeoSolar Technologies Inc.

  • GeoSolar Technologies is focused on revolutionizing the way we heat, cool and power homes with 100% natural energy sources
  • The company’s technology has been installed in multiple test homes in Colorado and achieved exceptional results
  • The GeoSolarPlus system combines solar power, geothermal ground-sourced energy and other clean energy technologies into one fully integrated system
  • The company’s leadership team includes some of the world’s most experienced and respected leaders in the field of decarbonization and sustainable homes
  • GeoSolar Technologies is currently accepting investment as part of a Regulation A+ offering

GeoSolar Technologies (“GST”) is a Colorado-based climate technology company and the creator of the Smart Green Home(R) system for newly built and existing residences and commercial buildings. The company is focused on revolutionizing the way we heat, cool and power homes with 100% natural energy sources. Its patent-pending integrated system harnesses energy from the earth and sun to power and purify homes and automobiles without the use of fossil fuels.

GeoSolar Technologies Inc. (“GST”) is a Colorado-based climate technology company and the creator of the Smart Green Home® system for newly built and existing residences and commercial buildings. The company is focused on revolutionizing the way we heat, cool and power homes with 100% natural energy sources. Its patent-pending integrated system harnesses energy from the earth and sun to power and purify homes and automobiles without the use of fossil fuels.

In a GST home, the sun’s energy is captured on the roof to generate all of the electricity required. Additionally, the consistent climate of the earth is used to keep the home at a perfect temperature year-round, and the company’s proprietary air purifying unit ensures that the air inside the home is safe and healthy.

GST’s home technology has been installed in multiple test homes in Colorado and achieved exceptional results, including some of the most impressive energy efficiency ratings (HERS) in the industry.

GeoSolar Technologies is currently accepting investment as part of a Regulation A+ offering. Everyone* can invest now for as little as $300. For more information, visit the company’s profile on Manhattan Street Capital and review its Offering Circular.

GeoSolar Technologies Inc. (“GST”) has been qualified by the U.S. Securities and Exchange Commission (SEC) to conduct a Regulation A+ capital raise. GST is already a publicly traded company who makes quarterly and annual filings with the SEC and is subject to quarterly PCAOB audits. This is the first time shares of GeoSolar Technologies are being made available for public purchase. Upon completion of this Regulation A+ offering, the company intends to seek a listing of its stock.


The Decarbonization Movement

Soaring and unstable energy/fuel costs continue to highlight the importance of rethinking the traditional approach to powering homes, from top to bottom. While most everyone is well aware of the remarkable, multi-trillion-dollar opportunity the electric vehicle transformation offers to investors (in addition to the benefits to the climate problem), few recognize that the all-electric home market is as large as electric vehicles and equally important to reducing carbon emissions.

U.S. energy expenditures clocked in at $3,891 per person in 2018, leading to estimated spending of $1.3 trillion on energy that year alone. Despite this, fewer than 3% of U.S. homes are currently powered by solar. This number is poised to increase exponentially as both new and existing residences transition to zero carbon models.

GST estimates that if all the homes in America were powered by its technology, carbon pollution could be reduced by an estimated 1.9 trillion pounds per year, greatly reducing the negative impacts on our climate.


The GeoSolarPlus (“GSP”) system combines solar power, geothermal ground-sourced energy and other clean energy technologies into one fully integrated system.
Key benefits of the GSP system include:

  • Making a real planet-changing difference in reducing air pollution
  • Eliminating or significantly reducing homeowners’ future utility bills
  • Enjoying lifetime energy independence and protection from price escalation and energy shortages
  • Eliminating greenhouse gas emissions from operation of home and daily life
  • Increasing home value
  • An integrated design for seamless operation of renewable energy systems
  • Maintaining a significantly healthier living environment
  • Leveraging existing renewable energy tax credits and electrification incentives
  • Creating stable jobs capable of supporting families in the decarbonized future

Click here to learn more about how GeoSolarPlus works.

Management Team

The GST leadership and management team includes some of the world’s most experienced and respected leaders in the fields of decarbonization and sustainable homes.

Stone Douglass is the Chairman and CEO of GST. He is a seasoned, 30-year public company executive and former Chairman and CEO of the Piper Aircraft Company.

Brent Mosbarger is the company’s Co-Founder and leads its commercial operations. He is a highly respected solar engineer whose experience includes roles with Chevron Energy’s green operations and serving as project manager and executive for a $400 million solar/geothermal innovation project.

Peter Romenesko is a Senior Strategic Advisor with GST. He brings to the company considerable experience as an engineer and large-scale project manager for Johnson Controls and Siemens.

Dr. Norbert Klebl is the company’s Co-Founder and Development Director. Recognized as one of the world’s leading experts in the field of zero-carbon innovation, he is a former McKinsey partner of 16 years with an MBA from Columbia.

Dar-Lon Chang is GST’s Director of New Product Development. Prior to joining GST, he had a 16-year career with ExxonMobil Energy Research. He received his PhD in engineering from the University of Illinois.

* Must be over 18, certain states are not currently available and will be added soon.

Recent News


Golden Matrix Group Inc. (NASDAQ: GMGI)

The QualityStocks Daily Newsletter would like to spotlight Golden Matrix Group Inc. (NASDAQ: GMGI).

  • Enhanced graphics, Gamification, AI-powered loyalty systems and data analytics redefining iGaming experience and generating higher player yields for online operators.
  • GMGI sets industry standard, offers 10,000+ games across 25+ providers
  • Company provides highly configurable, modular, white-label, turnkey gaming platforms compatible with all major operating systems, browsers, devices
  • Company recently reported 221% Q2-2022 growth, 15 consecutive profitable quarters 

Golden Matrix Group (NASDAQ: GMGI), a developer and licensor of online gaming platforms, systems, and gaming content, continues its steady growth trajectory by leveraging several emerging technology trends. In particular, the company is leveraging its go-to Loyalty platform that incorporates a Gamification component.

Golden Matrix Group Inc. (NASDAQ: GMGI), based in Las Vegas, Nevada, is an established gaming technology company that develops and owns online gaming IP and builds turnkey online casino solutions for gaming operators as well as configurable and scalable white-label gaming platforms for international customers, located primarily in the Asia-Pacific region. GMGI’s gaming IP includes tools for marketing, acquisition, retention and monetization of users. The company’s platform can be accessed through both desktop and mobile applications.

GMGI’s sophisticated software automatically declines any gaming or redemption requests from within the United States, in strict compliance with U.S. law.

Golden Matrix, through a subsidiary, also runs a pay-to-enter prize competition in the United Kingdom and Ireland.

The company’s shares began trading on the Nasdaq under the symbol ‘GMGI’ on March 17, 2022. Golden Matrix shares were previously traded on the OTCQX Best Market.

For the quarter ended January 31, 2022, the company reported revenue of $8.88 million, an increase of 355% over the same quarter one year earlier. Net income for the three-month period was $349,379, up from $52,158 a year earlier. It was the company’s 14th consecutive profitable quarter.

In December 2021, Golden Matrix announced it had entered into a purchase agreement to acquire a controlling ownership interest in UK-based RKingsCompetitions Ltd., one of Ireland’s and the United Kingdom’s leading independent online competition companies. RKings presents customers with paid and free entry routes to competitions that offer a range of prizes, including residential properties, luxury and exotic motor vehicles, holiday packages, technology packages and cash. The competitions are currently open only to residents of Ireland and the United Kingdom. Golden Matrix acquired an 80% ownership interest in RKings for cash and stock. The company also secured an option to purchase the remaining 20 percent interest of RKings, subject to certain requirements.

In March 2022, Golden Matrix announced it had applied for a Mexican gaming permit and, once approved, expects to offer online gaming in Mexico as well as roll out the RKings tournament business globally.


Golden Matrix Group develops fully operational online casino turnkey solutions as well as highly modular, configurable and scalable gaming platforms for its international customers in an effort to promote user acquisition, engagement, retention and monetization. The provided white label gaming platform is unparalleled in both mobile and desktop website deployment, proving compatible throughout all major operating systems and web browsers. In addition, the platform enhances the client’s ability to cater to various gaming scenarios including but not limited to transaction management and a range of loyalty and reward programs. Moreover, user engagement is optimized through the ability to accommodate both free and paid games.

The company’s GM-X System (and recently its next generation GM-Ag System) is considered the industry standard, granting access to over 10,000 games from more than 25 game providers. Through the GM-X System, Golden Matrix offers the industry’s most extensive game portfolio. The company’s gaming partners dominate the global online gaming market to deliver innovative games and premium brand titles. The GM-X System offers payment gateways that integrate with third party platforms or digital wallets. It supports all major currencies and offers multiple language options. The system’s data analytics provide the operator with a 360-degree view of the gaming platform’s performance.

GMGI currently supports over 500 unique casino brands and over 6 million players.

Market Outlook

Online gaming and sports betting sites and apps are increasingly taking market share from traditional location-based casinos. Widespread internet service availability and increasing use of mobile phones for playing online games from homes and public places is driving the market, according to a report from Grand View Research. In addition, factors such as easy access to online gambling, legalization and cultural approval, corporate sponsorships, and celebrity endorsements are also contributing to market growth. The growing availability of cost-effective mobile applications across the globe is further expected to fuel market growth.

This trend is only expected to accelerate as millennials reach their peak earning years and Gen Z youth begin to complete their education and move into careers. These generations are completely comfortable with online recreation, and with using technology like digital wallets and digital gameplay that underpins online gaming.

The global online gambling market was valued at $53.7 billion in 2019 and is expected to grow at a CAGR of 11.5% from 2020 to 2027 to reach a value of $127.3 billion, according to Grand View Research, with much of the growth expected from the U.S. and Asia. Even Europe, the most mature gaming market, is expected to grow at a rate of 20-25% year-over-year.

Management Team

Brian Goodman is CEO of Golden Matrix Group. He has more than 20 years of diverse senior management experience and business development roles within the technology and internet gaming industries. He has a tertiary science qualification as well as a marketing and sales background. His previous roles have been entrepreneurial and include CEO and senior management positions in smaller organizations, which he founded or in which he held equity, as well as multinational organizations.

Cathy Feng is COO at Golden Matrix. She is a co-founder of GMGI and holds a Master of Commerce degree. She has 10 years of experience as a financial officer in the technology and internet gaming industries. In past management positions, she interpreted, analyzed and presented financial and operation information to facilitate business decisions, grow companies and resolve complex problems. In addition, she has skills in marketing, business development, leadership and strategic planning.

Omar Jimenez is CFO and Chief Compliance Officer at GMGI. Prior to joining the company, he was CFO and COO of Alfadan Inc., a supplier of marine outboard engines. He has held senior financial management and operational positions at public and private companies including NextPlay Technologies, American Leisure Holdings, US Installation Group and Onyx Group. He holds various accounting professional certifications, including CPA and CPCU, and degrees in finance, accounting and business.

Henry Zhang is Chief Technology Officer at Golden Matrix. He oversees all aspects of development, integration and deployment of GMGI’s technology systems. He plays a key role in evolving GMGI’s technology business to lead and shape the industry. He is responsible for developing and scaling new businesses, including online gaming, eSport and P2P Systems. He was instrumental in launching the GM-X system and has been with the company for more than six years.

Golden Matrix Group Inc. (NASDAQ: GMGI), closed Tuesday's trading session at $4.37, off by 1.7978%, on 41,621 volume. The average volume for the last 3 months is 2,000 and the stock's 52-week low/high is $3.29/$10.72.

Recent News

Knightscope, Inc. (NASDAQ: KSCP)

The QualityStocks Daily Newsletter would like to spotlight Knightscope, Inc. (NASDAQ: KSCP).

Knightscope, Inc . [Nasdaq: KSCP], a developer of advanced physical security technologies focused on enhancing U.S. security operations, today announced that it received its second contract from a major US-based hotel brand. This Fortune 1000 hospitality company signed its first agreement in February 2022 for a Seattle property. The newest location set to add a K5 Autonomous Security Robot (ASR) to its public safety team is on the Big Island of Hawaii. The Knightscope Robot Roadshow was present for the client’s bi-annual gathering of its general managers held in Orlando, Florida in May. With over 5,000 properties in its native US market, the conference was highly attended and directly resulted in the acquisition of the latest contract. Knightscope is proud to be associated with such a powerful brand and optimistically anticipates expansion to more properties.

Knightscope, Inc. (NASDAQ: KSCP), founded in 2013 and based in Mountain View, California, is a leader in the development of autonomous security capabilities targeting to disrupt the $500 billion security industry. Knightscope’s technology uniquely combines self-driving technology, robotics, artificial intelligence and electric vehicles.

Knightscope designs and builds Autonomous Security Robots (ASRs) that provide 24/7/365 security to the places you live, work, visit and study. The company’s client list covers public institutions and commercial business operations, including multiple Fortune 1000 companies to date. These ASRs have been proven to enhance safety at hospitals, logistics facilities, manufacturing plants, schools and corporations. ASRs act as highly cost-effective complementary systems to traditional security and law enforcement officials, providing an additional advantage by continuing to offer uninterrupted patrolling capabilities across the country.

The company’s ASRs have assisted in the arrest of suspects involved in crimes ranging from armed robbery to hit-and-runs. Their machine-embedded thermal scanning capability even aided in preventing the breakout of a major fire. You can learn more about the crime fighting wins at

The company has achieved several milestones since its creation in 2013, including:

  • Establishing itself in a 15,000-square-foot facility located in Mountain View, California, in the heart of Silicon Valley, where Knightscope designs, engineers and builds its technology (Made in the USA)
  • Operating for more than 1 million hours in the field and securing contracts across five time zones, from Hawaii to Rhode Island
  • Raising over $100 million since inception to build its technology from scratch and generating over $13 million in lifetime revenue, validating both the market opportunity and the technology

Growth Capital & Proposed Nasdaq Listing

With backing from more than 28,000 investors and four major corporations and over $100 million raised since inception, Knightscope is poised to be an industry leader in the future of public safety and security.

On December 1, 2021, Knightscope announced the commencement of an offering of up to $40 million of its Class A common stock, with shares to be listed immediately following closing on the Nasdaq Global Market under the ticker symbol ‘KSCP’. The offering is for up to 4 million shares priced at $10 per share. Learn more at

Company Mission – Reimagining Public Safety

Knightscope’s long-term vision has an eye on the greater good. The company’s mission is to make the United States of America the safest nation in the world while supporting the 2+ million law enforcement and security professionals across the country.

Crime has an estimated negative economic impact in excess of $2 trillion annually. As crime is reduced, positive impacts will likely be realized across several aspects of society, including housing, financial markets, insurance, municipal budgets, local business and safety in general.

Knightscope CEO William Santana Li was interviewed by Kevin O’Leary, more commonly known as Shark Tank’s Mr. Wonderful. When asked to explain how the benefits provided by the ASRs outrank a human doing the same job, Li said, “First, just the simple presence of a physical deterrent causes criminal behavior to change. Second, the machines are self-driving cars that patrol all around and recharge themselves. They also generate 90 terabytes of data per year. No human would ever be able to process that. The robots are intended to be eyes and ears for the humans, not a one-to-one replacement.”

The Knightscope solution to reduce crime combines the physical presence of ASRs, sometimes referred to as proprietary Autonomous Data Machines, with real-time onsite data collection and analysis. The ASRs are fitted with eye-level 360° cameras, thermal scanning, public address announcements and various other features that work in tandem with humans to provide law enforcement officers and security guards unprecedented situational awareness.

Those 90 terabytes of data are then formatted in a useable way, so law enforcement can leverage that information and execute their responsibilities more effectively.

Public Safety Innovation

The company’s recurring revenue business model is set up to mimic the recurring societal problem of crime, and it takes into consideration the fact that innovation in the security and public safety industry has been stagnant for decades. Because the traditional practices of the sector have remained unchanged for years, automation has potential to drive substantial cost savings – and significant improvement in capabilities.

Human security guards are one of both the largest expenses and the largest liabilities for companies. Knightscope’s robots are offered at an effective price of $3 to $9 per hour, compared with approximately $85 for an armed off-duty law enforcement officer and $15 to $35 for an unarmed security guard.

This innovation has the potential to drive considerable cost savings. Based on these estimates, manufacturing costs can be recovered as soon as the first year of operation.

Product Offerings

The company has nine patents and a framework of unique intellectual property. Knightscope currently offers a K1 stationary machine, a K3 indoor machine and a K5 outdoor machine. A K7 multi-terrain four-wheel version is in development.

The ASRs autonomously patrol client sites without the need for remote control, providing a visible, force multiplying, physical security presence to help protect assets, monitor changes in the area and deter crime. The data is accessible through the Knightscope Security Operations Center (KSOC), an intuitive, browser-based interface that enables security professionals to review events generated by the ASRs providing effectively ‘mobile smart eyes and ears’. Learn more at

The ASRs and the related technologies were developed ground up by the company and are Made in the USA.

The Robot Roadshow

Knightscope has created the ultimate hybrid physical and virtual event, bringing its Autonomous Security Robot technologies to cities across the country for interactive and in-person demonstrations.

Each roadshow landing is hosted virtually by a Knightscope expert, and visitors can interact directly with each of the company’s ASRs and see the Knightscope Security Operations Center (KSOC) user interface in action. Learn more at

Management Team

Chief Executive Officer William Santana Li is a veteran entrepreneur, a former executive at Ford Motor Company and the founder of GreenLeaf, a company that grew to be the world’s second-largest automotive recycler and is now part of LKQ Corporation (NASDAQ: LKQ).

Chief Client Officer Stacy Dean Stephens brings his experience as a former Dallas law enforcement officer, as well as his skills as a seasoned entrepreneur, to assist on the client acquisition side.

Chief Intelligence Officer Mercedes Soria is an award-winning technologist and former Deloitte software engineer.

Chief Design Officer Aaron Lehnhardt brings over two decades of two- and three-dimensional product and industrial design in modeling and VR to the table, on top of his experience as a senior designer at Ford Motor Company.

Chief Financial Officer Mallorie Burke is a seasoned financial executive and strategic advisor for both private and publicly traded technology companies with a successful track record of mergers & acquisitions, corporate growth and exit strategies, including public listings.

General Counsel Peter Weinberg leverages 30 years of diverse corporate counsel experience, spanning from startups to well-established companies, private and public. He has significant experience training personnel at all levels in critical areas to improve corporate compliance and productivity.

Knightscope, Inc. (NASDAQ: KSCP), closed Tuesday's trading session at $3.04, off by 5.2959%, on 477,638 volume. The average volume for the last 3 months is 105 and the stock's 52-week low/high is $2.87/$27.50.

Recent News

Cybin Inc. (NEO: CYBN) (OTC: CYBN)

The QualityStocks Daily Newsletter would like to spotlight Cybin Inc. (NEO: CYBN) (NYSE American: CYBN).

Clinilabs Drug Development Corporation, a global, full-service contract research organization with deep expertise in central nervous system drug development, today announced commencement of enrollment in a phase 1/2a clinical trial of CYB003. Being developed by Cybin (NYSE American: CYBN) (NEO: CYBN), a leading ethical biopharmaceutical company focused on progressing “Psychedelics to Therapeutics(TM),” CYB003 is the first novel psilocybin analog to be evaluated in phase 1/2a development for the treatment of major depressive disorder (“MDD”). “Clinilabs is honored to be working with Cybin, an innovator in the development of novel psychedelic therapeutics, to conduct its first-in-human clinical trial of CYB003,” said Clinilabs Vice President of Strategy and Corporate Development Jeanine Falinski. “We are excited by the potential of these therapeutics and hope that the future is life-changing for individuals suffering from mental illness. We are encouraged by the interest from potential research participants who have already come forward prior to today.” To view the full press release, visit

Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) is a Canada-based life sciences company focused on the pharmaceutical development of psychedelic products, as well as the functional mushroom market.

The early-stage company boasts an experienced management team featuring industry veterans from pharmaceutical and consumer product backgrounds who have run multiple clinical trials and collectively helped facilitate billions of dollars in product revenues. The team is dedicated to the development of products and protocols within the psychedelic, pharmaceutical and nutraceutical industries.

In particular, Cybin aims to further build upon and expand its intellectual property (IP) portfolio, which is structured around unique psilocybin delivery mechanisms that target a number of different therapeutic indications. In addition, the company has dedicated itself toward furthering its research and IP within the fields of synthetic compounds, extraction methods, the isolation of chemical compounds, new drug formulations and protocol regimes.

Serenity Life Sciences & Natures Journey Inc.

The company’s business model is centered around its two core subsidiaries, Serenity Life Sciences and Natures Journey Inc., which comprise Cybin’s two-pronged approach toward delivering fungi-derived psychedelic and medicinal products.

Serenity Life Sciences is focused on furthering research and development of psilocybin-based medications. Psilocybin is found in certain species of mushrooms and is a non-habit forming, naturally occurring psychedelic compound. Research into psilocybin has shown positive results for the treatment of depression, anxiety, PTSD, addiction, eating disorders, ADHD and other indications.

Natures Journey Inc. operates the Journey brand, which specializes in developing proprietary medicinal mushroom products that target and promote mental wellness, immune boosting detoxification and overall general health and wellbeing.

Partnership with the Toronto Centre for Psychedelic Science (TCPS)

Staying true to its axiom of being a research-first medicinal mushroom life sciences company, Cybin recently announced its entry into a strategic partnership with the Toronto Centre for Psychedelic Science (TCPS), with the goal of furthering its ongoing psilocybin research efforts and expanding Cybin’s psilocybin IP portfolio (

“While there is evidence to support psilocybin as a treatment for certain indications, the Toronto Centre for Psychedelic Science is taking a clinical approach to prove or disprove the safety and efficacy of psilocybin-based microdosing through an open science approach,” Paul Glavine, CEO of Cybin, stated in a news release.

“We are excited to join forces with Cybin and to offer our expertise. A number of firms had approached TCPS, but Cybin demonstrated a superior commitment to high-quality research and integrity in product development. Our high standards for scientific rigor and transparency will find a fitting home within the culture Cybin is cultivating in Canada and abroad,” Thomas Anderson, co-founder of the Toronto Centre for Psychedelic Science, added.

Journey’s Product Monetization & Market Potential for Nutraceutical Supplements

Although Cybin is at the forefront of companies seeking to conduct clinical trials aimed at gaining regulatory approval for psilocybin and other psychedelic products, the company has also placed a great deal of emphasis on generating meaningful revenue from its very outset.

Cybin’s Journey brand has is launching a range of supplements comprised of popular fungi-derived ingredients such as Reishi, Lion’s Mane and Cordyceps. Purported to aid focus and concentration while promoting neurogenesis, Journey’s range of nutraceutical products provides Cybin with a crucial foothold within the non-psychedelic legal supplement market, which is valued at over $25 billion globally and growing at a 9% year-over-year rate.

Pharmaceutical Psychedelics

In addition to the company’s range of non-psychedelic supplements, Cybin has plans to carry out a clinical trial with a new delivery system for its psilocybin-based medications later this year. Ultimately, the company aims to enter into technology transfer agreements with global pharmaceutical companies after phase 1 & phase 2 clinical trials are complete in order to accelerate regulatory approvals in major indications in global markets with entire lifecycle product management.

With products such as psilocybin truffles already legal in nations such as the Netherlands, Jamaica and Bulgaria, Cybin has positioned itself to capitalize on an eventual legalization of psychedelic mushroom-derived products in the future. Working within a regulatory environment with strong similarities to that which dealt with cannabis prior to the industry’s eventual legalization by the Canadian government in 2018, Cybin is laying the groundwork for the moment pharmaceutical psychedelics gain acceptance in North America and abroad.

Amalgamation Agreement and Financing

Cybin recently announced its entry into an amalgamation agreement dated June 26, 2020, with Clarmin Explorations Inc. (TSX.V: CX) and 2762898 Ontario Inc., a wholly owned subsidiary of Clarmin ( Completion of the transactions contemplated in the amalgamation agreement will result in the reverse takeover of Clarmin by Cybin.

In connection with the proposed transaction, Cybin plans to complete a “best-efforts” brokered private placement of subscription receipts of Cybin, with a syndicate of agents co-led by Stifel Nicolaus Canada Inc. (Stifel GMP) and Eight Capital, to raise a minimum of C$14 million ($10 million) and a maximum of C$21 million ($15 million), with a 15% agents’ option.

To date, Cybin has raised approximately C$10,400,000 through an initial financing round and its series A financing round.

Cybin Inc. (NEO: CYBN) (NYSE American: CYBN), closed Tuesday's trading session at $0.5733, off by 0.984456%, on 359,356 volume. The average volume for the last 3 months is 1.836M and the stock's 52-week low/high is $0.3903/$3.38.

Recent News

Home Bistro Inc. (OTC: HBIS)

The QualityStocks Daily Newsletter would like to spotlight Home Bistro Inc. (OTC: HBIS).

Home Bistro (OTC: HBIS), a leading online meal-delivery platform that offers celebrity chef-inspired, gourmet and lifestyle ready-made meals, is planning on rolling out a new three-tiered pricing plan, effective Aug. 1, 2022. The announcement comes after the company saw positive results from beta testing of the enhanced meal-pricing structure. “Over the past six months, we have spent considerable time studying ways to reduce our product costs while expanding our top line revenue and increasing gross profit margin,” said Home Bistro CEO Zalmi Duchman in the press release. “By analyzing the current market and closely studying the value proposition of alternative products, we believe we are now properly positioned to lowering prices for our customers. Recognizing that we offer a premium product, our goal was to offer our all of our meals for under $20 while maintaining our premium product positioning and increasing profitability. From the initial positive results of our beta test, we believe we can accomplish this as we continue taking aggressive measures toward decreasing our expenses, increasing our gross profit margin and achieving profitability in 2023.” To view the full press release, visit

Home Bistro Inc. (OTC: HBIS) is a Miami-based company engaged in the business of providing prepackaged and prepared meals to consumers. The company has created the next generation of prepared meal delivery – Ready-Made Gourmet Meal Delivery 3.0.

Home Bistro addresses the three major problems facing the prepared food delivery market: poor food quality; customers tired of eating the same meals; and, eating at home is still eating at home, with the accompanying food preparation and clean up chores. The company addresses these problems by delivering high quality food fresh and fast, providing customers a variety of meal choices from a diverse lineup of celebrity chefs, and requiring simple prep and easy clean up without sacrificing the fine dining experience.

Home Bistro offers a family of high quality, direct-to-consumer, ready-made, gourmet meals. Using the latest fresh food “skin-packing” technology, Home Bistro offers a virtual “Bistro Emporium” where consumers can cross select from a wide variety of siloed “bistros,” each with a dedicated section and unique visitor experience created by a renowned celebrity/executive chef. Meals delivered fresh can be eaten within 10 to 14 days or frozen for up to six months.

The company’s mission is to lead the next generation of heat-to-eat food delivery with unique and delicious cuisine and an experience that excites the market. Home Bistro’s advantage in the highly competitive meal delivery space is meal diversity – with the best celebrity chefs from around the world, offering a home-based fine dining experience through a selection of over 50 unique gourmet meals, as well as offering a developing selection of desserts and single-serving wine to perfectly complement the meal experience. In addition, the company uses only the highest quality ingredients in its meals and preserves their freshness by employing state-of-the-art vacuum skin packing.

In mid-2021, Home Bistro acquired southern-California based Model Meals, a lifestyle ready-to-eat meal prep service, which is Whole30 and Paleo approved, while then only serving three states. In September 2021, Home Bistro commenced shipping Model Meals to all 50 states and recently announced that it will launch a subscription-based service for Model Meals consisting of three meals per day (breakfast, lunch and dinner) for up to five days per week. The subscription service, expected to launch by May 2022, will initially target the Southern California market, where Model Meals maintains a food production and fulfillment facility and enjoys a strong customer base.

Brands and Products

Home Bistro’s leading online platform ( provides direct-to-consumer, heat-to-eat, celebrity chef-inspired gourmet meals. Offerings currently include inspirations developed by “Iron Chef” Cat Cora, two-time New York Times best-selling cookbook author and TV host Ayesha Curry, sports-tailgating focused creator of “Hungry Fan” Chef Diana Falk, “Master Chef” Claudia Sandoval, and “Top-Chef All-Star” Richard Blais. Soon-to-launch celebrity chefs on the Home Bistro platform include “Caterer to the Stars” Roblé Ali, “zero-waste cooking” celebrity chef Priyanka Naik, and CHOPPED champion Melanie Moss.

Home Bistro’s Model Meals lifestyle brand ( is a Whole30 and Paleo approved, ready-to-eat meal prep service, offering a weekly rotating menu that is prepared by professional chefs, using only the highest quality ingredients available, sourced responsibly and locally, and delivered in sustainable, eco-friendly packaging.
Home Bistro has partnered with celebrity chef Melanie Moss to expand its dessert menu options. In keeping with its mission to deliver a complete gourmet culinary experience to discerning customers, Home Bistro beta-tested its first dessert – a delicious, sweet and salty caramel brownie. Based on the encouraging results, the company is moving forward to create a much more robust dessert menu.

Home Bistro has formally launched its wine offering initiative with In Good Taste Wines, a unique direct-to-consumer wine platform that empowers wine lovers to “discover the world, by the glass.” The company has worked diligently with the In Good Taste Wines team to develop a unique selection of elegant single-serving wines to pair with Home Bistro’s celebrity chef-inspired meals. The partnership with In Good Taste Wines provides Home Bistro with a low-cost, incremental source of revenue, which will assist the company in expanding its gross profit margin and lead it to faster profitability.

Market Outlook

Global revenue in the online food delivery sector was $136 billion in 2020 and forecast to grow steadily at a 7.5% CAGR through 2024 to a projected value of $182 billion.
In the U.S., the food delivery sector, which comprises both the restaurant-to-consumer segment and the platform-to-consumer segment where Home Bistro operates, is expected to surpass $32.3 billion in 2024. The company’s addressable market, the platform-to-consumer segment, is approximately 30% of the U.S. market and is projected to reach a value of $9.7 billion by 2024. This segment is expected to grow even faster than the sector as a whole as providers refine their focus on healthier meals, more convenient delivery and subscription options and more advanced meal processing technology.

Management Team

Zalmi Duchman is Chairman and CEO at Home Bistro. He was CEO and founder of The Fresh Diet online meal delivery service, which grew from a startup to over $30 million in annual revenue. He is a thought leader, investor and publisher of numerous articles in the food tech sector. He was named one of Forbes “America’s Most Promising CEOs Under 35,” and was named a Miami Herald “20 Under 40” entrepreneur in 2014.

Carlo Ricci is Director of Operations at Home Bistro. He was VP Operations for The Fresh Diet online meal delivery service, where he developed the culinary and R&D departments and established distribution centers in five states. He was also Operations Manager at Homemade Meals, where he developed and implemented inventory systems, established production facilities on both coasts and trained and managed personnel. He has a bachelor’s degree in data analytics from Miami Dade College.

Camille May is CFO at Home Bistro. She is a co-founder of Model Meals meal delivery service, where she has served as CFO since the company’s inception in 2015. She helped build the company from the ground up to more than $2 million in annual revenue. Prior to Model Meals, she worked as a financial analyst and broker in commercial real estate. She has a BBA in finance from the Leeds School of Business at the University of Colorado.

Danika Brysha is Chief Marketing Officer at Home Bistro. She co-founded Model Meals and was also a co-founder of the Self-Care Society. She is a former fashion model and founder of Danika Brysha Inc., a service specializing in modeling, coaching, speaking, events, media and influence. She is creator of the Brunch Series and a Whole30 certified coach. She is also host of the top-rated podcast “Light + Life Live” and is a lifestyle design expert. She earned a bachelor’s degree from the University of Colorado.

Home Bistro Inc. (OTC: HBIS), closed Tuesday's trading session at $0.2, off by 29.8369%, on 100 volume. The average volume for the last 3 months is 39,102 and the stock's 52-week low/high is $0.125/$1.98.

Recent News

Odyssey Group International Inc. (OTC: ODYY)

The QualityStocks Daily Newsletter would like to spotlight Odyssey Group International Inc. (OTC: ODYY).

Odyssey Health (OTC: ODYY), f/k/a Odyssey Group International Inc., a company focused on developing unique, life-enhancing medical products, today announced the completion of all three cohorts in its Phase I Single Ascending Dosing (“SAD”) clinical trial. According to the update, Odyssey’s trial involves administering PRV-002, the company’s novel drug to treat concussion, to healthy human subjects. Concussions represent an “unmet” medical need and affect millions worldwide, while a single concussion can significantly increase the risk of Alzheimer’s and other neuropsychiatric disorders. “After reviewing the data from Cohort III and completing the SAD analysis, I have strong confidence that PRV-002 will continue to show safety during the Multiple Ascending Dosing (‘MAD’) portion of the Phase I clinical trial where subjects are treated once daily for five straight days,” said Dallas Hack, MD, member of the Safety Review Committee. “We have unanimously approved the start of MAD Cohort I. I am especially excited to see the overall low levels of PRV-002 in the blood supporting the hypothesis that more drug is getting to the brain itself when administered with the intranasal device. If this turns out to be the case, not only can the targeted effects of the drug be more efficacious the drug will likely have less potential side effects.” To view the full press release, visit Traumatic brain injuries are among the most difficult injuries to recover from. On top of causing issues such as speech difficulties and problems with logic, studies have found that individuals who sustain long-lasting symptoms from their injuries are more likely to develop mental health problems, including  post-traumatic stress disorder (PTSD), depression and suicidal thoughts. Up to 30% of those who survive brain injuries go on to develop post-concussion syndrome, a condition that refers to long-term symptoms after a concussion. Common symptoms of post-concussive syndrome include headaches, brain fog, nausea, blurry vision and memory problems. As more efficacious concussion treatments become available from companies such as Odyssey Health Inc. (OTC: ODYY), the likelihood of complications resulting from concussions could lessen and possibly reduce incidents of suicidal ideation or even attempts.

Odyssey Group International Inc. (OTC: ODYY) is a medical technology company focused on developing lifesaving medical products that offer technological and clinical advantages over current standards of care.

The company’s portfolio of product technologies is diverse, featuring four unique medical products in development. Odyssey’s goal is to deliver superior products with enhanced clinical utility and market potential, thereby yielding a high rate of return for its shareholders and partners. It is guided by a senior management team with significant experience relating to refining technologies, building commercial systems and forging strategic partnerships.

Product Portfolio


Odyssey has two pharmaceutical products in development:

  • PRV-002 is a novel compound for the treatment of concussion, which currently has no FDA-approved drug. In pre-clinical studies, PRV-002 has been shown to significantly improve both neuroscore and memory score following injury in rats subjected to concussion models. Importantly, the first-in-class novel neurosteroid demonstrated no drug-related toxicity in these trials.
    • PRV-002 is currently being evaluated in a phase I clinical trial for the treatment of concussion, with phase II trials planned for launch in Fall 2022. Odyssey has also highlighted the potential of PRV-002 for additional indications such as Alzheimer’s disease, Parkinson’s disease, ALS and chromic traumatic encephalopathy (CTE).
  • PRV-001 is a novel compound intended to treat Niemann-Pick disease, a rare neurodegenerative-lysosomal storage disorder that affects an estimated 1 in 150,000 individuals in the U.S., demonstrating a 5x higher incidence in Middle Eastern populations.
    • Odyssey expects to receive Orphan Drug designation from the FDA for PRV-001, which would accelerate its pathway to FDA approval and provide seven years of market exclusivity.

Medical Devices

Odyssey is also developing two medical device candidates:

  • CardioMap® is intended to provide early, non-invasive testing for heart disease. The system offers a number of potential advantages over traditional EKGs, including requiring less training to operate, offering heightened sensitivity and coming in a small and portable form factor. CardioMap is being developed for a 510(k) regulatory pathway, which requires a study to demonstrate equivalence to legacy EKG offerings.
    • When approved, CardioMap is expected to be the only device in its class that has a predictive value, illustrating ‘grey’ areas where deterioration has begun but not yet led to pathology. Odyssey expects this feature to provide a powerful incentive for doctors to use the CardioMap device in end markets such as hospitals, doctors’ offices, rehabilitation centers and sports medicine practices.
  • Save-A-Life (SAL) is a patented, single-action, instantaneous, handheld, mechanical anti-choking device that creates a vacuum chamber in the mouth to dislodge throat obstructions in a matter of seconds, all without harm to the victim. The device is currently in development, with a proof of concept established.
    • Odyssey believes that, once FDA-approved, its anti-choking device will quickly become the “accepted” standard and leader in the treatment of choking incidents globally. Its low-cost manufacturing and convenient portable design give SAL a competitive edge over competing devices utilizing cumbersome masks.

Market Opportunities

Odyssey’s varied development pipeline positions it to address a number of sizable market opportunities with significant unmet medical need. Concussions alone currently account for medical costs of roughly $10-15 billion annually in the U.S., despite the lack of a currently approved FDA drug treatment. This need is particularly apparent in the military and sports industry, where the likelihood of athlete head-injury recurrence is estimated at 75%.

It is for this reason that, in March 2021, Odyssey announced the formation of a sports advisory board featuring well-known athletes supporting the company’s efforts to enhance public awareness of traumatic brain injuries and concussions, as well as the need for an FDA-approved therapy. Members of Odyssey’s sports advisory board include NFL Hall of Famers Kurt Warner & Brett Favre and two-time Olympic gold medalist Abby Wambach.

With its CardioMap platform, Odyssey is targeting the global cardiac monitoring market, which was valued at $28 billion in 2021 by Insight Partners and forecast to reach $43 billion by 2028.

Save-A-Life targets a similarly underserved market. Choking is the fourth-leading cause of death in children, and approximately 5,000 choking deaths occur each year in the U.S. While 95% of these deaths result from in-home incidents, current choking rescue devices fail to address in-home applications.

Management Team

Joseph Michael Redmond is the President, CEO and Chairman of Odyssey. He has over 30 years of commercial experience in medical device companies, previously serving as CEO of Parallax Health Sciences Inc., V.P. of Business Development for DxTech Inc. and V.P. of Sales and Marketing for Bioject Medical Technologies Inc. While at Bioject, Mr. Redmond helped raise over $15 million in capital, entered into several licensing and distribution deals with major biotech and pharmaceutical companies and grew the market cap of the company from under $10 million to over $400 million. He started his career at Abbott Labs and holds a B.A. from Denison University.

Christine M. Farrell is the company’s CFO and Secretary. Prior to joining Odyssey, Ms. Farrell was Vice President of Finance for Bioject Medical Technologies Inc. She also held accounting and financial management positions with Spar-Tek Industries, a manufacturer of high quality and cutting-edge technology for the plywood industry, and Action Machinery, a seller of new and used robotic machine tools and equipment. Ms. Farrell holds a B.A. in Accounting from the University of Washington and an M.B.A. from Willamette University.

Dr. Jacob W. Vanlandingham is Odyssey’s Head of Drug Development. Dr. Vanlandingham holds a Ph.D. in neuroscience with a molecular biology focus. He is a member of the Society for Neuroscience, American Society for Nutritional Sciences, National Neurotrauma Society, Faculty for Undergraduate Research in Neuroscience and the International Association of Medical Science Educators.

Odyssey Group International Inc. (OTC: ODYY), closed Tuesday's trading session at $0.18955, off by 9.7381%, on 137,527 volume. The average volume for the last 3 months is 324,409 and the stock's 52-week low/high is $0.11/$0.65.

Recent News

Eat Well Investment Group Inc. (CSE: EWG) (OTC: EWGFF)

The QualityStocks Daily Newsletter would like to spotlight Eat Well Investment Group Inc. (CSE: EWG) (OTC: EWGFF).

  • Plant-based foods investment company Eat Well Investment Group Inc. has positioned itself to respond to global food needs exacerbated by the COVID pandemic and the war in Ukraine, and it reports its subsidiaries are in the right place to help deal with food sector concerns
  • Eat Well recently announced its annual financial data and Q1 2022 data, showing its Amara baby food subsidiary achieved revenue gains of 320 percent this year over the previous year
  • The company also reported it is on target to achieve this year’s revenue goals of $90 million to $110 million

Fears that a recession will overtake the global economy have roiled the marketplace for weeks, although analysts see some optimism in consumers’ ongoing willingness to spend for concerts, movies, travel and other experiences people missed during the height of the pandemic ( Eat Well Investment Group (CSE: EWG) (OTC: EWGFF) (FRA: 6BC0), a publicly-traded investment company, today announced it has promoted its Vice President, Finance Patrick Dunn to CFO and has appointed him as a member of the company’s board of directors. Dunn, CPA, a founding partner of Dunn, Pariser & Peyrot, is an experienced senior executive with a proven track record of investing in and building highly successful agribusinesses throughout North America. “We are proud to promote Patrick Dunn to CFO of Eat Well Group and to have him join the board of directors of the company. His first-hand experience in investing in, building and scaling plant-based food companies across international jurisdictions is a tremendous asset,” said Marc Aneed, the company's president, CEO and director. “Mr. Dunn has served as the company’s vice president of finance since the company refocused its investment policy on agribusiness, food tech and plant-based foods nearly one year ago. He knows the industry, the company, and everything plant-based inside out and will be a tremendous asset...” To view the full press release, visit

Eat Well Investment Group Inc. (CSE: EWG) (OTC: EWGFF), headquartered in Vancouver, British Columbia, is a publicly traded vertically integrated plant-based foods company combining the best of agribusiness, foodtech, and CPG brands to supply the world with innovative, delicious, and better-for-you foods. The company supplies Beyond Meat, Ingredion, Nestle, General Mills and more. It is on track to generate $60 million in revenue for 2021 and is projecting $100 million in revenue for 2022.

Eat Well’s management team has an extensive record of sourcing, financing and building successful companies across a broad range of industries and maintains a current investment mandate on the health and wellness industry. The team has financed and invested in early-stage venture companies for more than 25 years, resulting in the ability to construct a portfolio of opportunistic investments intended to generate superior risk-adjusted returns. Eat Well’s strategic advisory board includes pioneers in the plant-based foods industry, including HRH Prince Khaled bin Alwaleed bin Talal Al Saud, Founder and Chief Executive Officer of KBW Ventures, and Jeff Dunn, CEO of Bolthouse Farms who previously held senior leadership positions at both Campbell Soup Company and The Coca Cola Company.

The company’s plant-based investment thesis is centered on growing its seed-to-market operations, which include raw ingredients, processing, pulse fractionation, unique IP and premium consumer packaged goods (CPG). Eat Well Group is building a unique ecosystem that can supply these essential cornerstone needs for society. The company has plant-based foods and nutrition experts specializing in the latest science and original thinking for what consumers want most – high quality and affordability in healthy, clean and simple products.

Eat Well focuses on intellectual property, product portfolio development and long-term value creation for stakeholders in a rapidly expanding industry. As an emergent sector globally, plant-based foods represent a double-digit annual growth category, with more than 35% of the world’s supply of pulse proteins coming from Canada.


On July 31, 2021, Eat Well Group acquired Belle Pulses Ltd., one of the top pulse processors in Canada. Belle Pulses has been operating for over 40 years and had over $60 million in sales in 2020. The company counts a broad range of customers in over 35 countries, including global strategic food companies and major ingredient distributors. Currently, Belle produces nearly 100,000 tons of fully traceable seed and product, yielding over 26,000 tons of pure plant protein.

Eat Well also owns 100% of Sapientia Technology Inc. Led by Dr. Eugenio Bortone – one of the world’s preeminent food scientists and extrusion processing experts and the inventor of Frito-Lay’s Twisted Cheetos – Sapientia has filed four patents around the “protein curl” and crispy-puff-style snack. By focusing on texture and crunch, Sapientia’s patents solve one of the major problems that large scale snack food companies have struggled with for years – how to offer appealing texture and flavor in a guilt-free, not fried, natural and healthy alternative to the majority of snack food products available today.

Eat Well owns a 51% share of Amara Organic Foods, with an option to acquire additional ownership up to 80 percent. Amara, one of the fastest-growing baby food brands in America, is a food technology company that uses science and proprietary IP that locks in taste and texture to make healthy, organic, non-GMO, plant-based, convenient baby and children’s food possible for modern-day families. From baby food to toddler food and beyond, Amara is driven by the belief that setting kids on the right path from a young age will help them live better, feel better and think better for the rest of their lives. Amara’s revenues have grown by more than 400% since January 2021, and the brand’s success has drawn media coverage from business news outlets including Forbes and TechCrunch.

Market Outlook

According to an August 2021 report from Bloomberg Intelligence, the plant-based foods market is expected to experience explosive growth, comprising up to 7.7% of the global protein market by 2030 at a value of over $162 billion, up from $29.4 billion in 2020. Bloomberg notes that plant-based alternatives are here to stay, and that consumption will grow rapidly. Plant-based food sales in 2020 grew twice as fast as overall food sales, according to Polaris Market Research.

Pulse proteins (fava, yellow pea, etc.) are a foundational ingredient to most plant-based foods due to their high protein content and their readily available, affordable supply.

Many analysts view the food tech market as similar to the early days of the Internet in that plant-based foods represent a worldwide secular trend of steady growth and potential that will revolutionize the way society functions and people experience nutrition.

The sector continues to experience significant M&A transactions. Recently, Sol Cuisine was acquired by PlantPlus Foods LLC, a major South American protein producer, in an all-cash transaction valued at approximately $126 million, or 6x revenue.

Management Team

Marc Aneed is President and Director of Eat Well Group. His 20-year career in CPG started at The Quaker Oats Company/PepsiCo, where he worked on iconic brands like Gatorade. He previously was at Glanbia PLC, a global nutrition company, where he led Amazing Grass, a leading plant nutrition and supplement company with over $100 million in retail sales. He also led Glanbia’s Sports Nutrition brands in North America with over $750 million in retail sales. Mr. Aneed has launched dozens of successful consumer products, driving over $1 billion in collective retail sales.

Mark Coles is the company’s Chief Investment Officer. He is a veteran CPG senior executive specializing in the plant-based foods sector. For the past decade, Mr. Coles has spearheaded global plant-based start-up initiatives, culminating in a 2020 acquisition by an international New York Stock Exchange-listed food ingredient company. He has over 25 years of experience in CPG-focused strategy, mergers and acquisitions and project financing.

Patrick Dunn is Eat Well Group’s Vice President, Finance. He is the founding partner of Dunn, Pariser & Peyrot and has a track record of building highly successful agribusinesses throughout North America and other international markets. As a testimony to his business portfolio work, Mr. Dunn and his firm have won multiple industry awards for accounting, finance and business management.

Barry Didato is the company’s Vice President, Strategy. He is focused on the development of strategic revenue channels, sales partnerships, and international distribution for Eat Well Group. Mr. Didato brings extensive strategic sales capabilities and an extensive network of contacts in the industry to the company. Prior to joining Eat Well Group, he served for over 18 years as a senior advisor for several ultra-high net worth family offices and numerous innovative wellness, nutrition, medical, and food businesses.

Strategic Advisory Board

HRH Prince Khaled bin Alwaleed bin Talal Al Saud, Founder and Chief Executive Officer of KBW Ventures, is a firm supporter of clean energy and the humane treatment of animals. He is also a vocal supporter of the private sector in the Middle East. A member of the Saudi Arabian Royal Family, Prince Khaled was born in Stanford and spent his youth in Riyadh under the mentorship of his father, philanthropist HRH Prince Alwaleed bin Talal Al Saud, Chairman of Kingdom Holding Company. He is also the Founding Chairman of KBW Investments and serves across several boards. He invests in an array of successful but diverse global businesses – from promising technology startups to established companies. Today, with holdings on three continents, Prince Khaled stands at the gateway between the Middle East’s evolving economies and the Western world. Consistently, Prince Khaled’s focus is on ventures and ideas at the intersection of innovation and economic growth.

Jeff Dunn has over 30 years of experience in agriculture and packaged food, including senior leadership positions with Bolthouse Farms, Campbell Soup Company and The Coca Cola Company, among others. He is an Operating Partner at Butterfly and focuses primarily on the agriculture & aquaculture and food & beverage product sectors. Prior to joining Butterfly, Mr. Dunn was the President of the Campbell Fresh division of Campbell Soup Company from 2015 to 2016, where he was in charge of building Campbell’s scale and accelerating its growth in the rapidly expanding packaged fresh segments and categories across the retail perimeter.

Eat Well Investment Group Inc. (OTC: EWGFF), closed Tuesday's trading session at $0.1539, off by 7.623%, on 27,000 volume. The average volume for the last 3 months is 286,168 and the stock's 52-week low/high is $0.1368/$1.00.

Recent News

Cannabis Strategic Ventures Inc. (OTC: NUGS)

The QualityStocks Daily Newsletter would like to spotlight Cannabis Strategic Ventures Inc. (NUGS).

Learning proper storage techniques is crucial for cannabis businesses, especially those looking to succeed in the highly competitive and cutthroat cannabis concentrates segment. Storing cannabis flower isn’t difficult, but improper storage can steadily degrade the cannabis and even lead to the growth of mold. Concentrates, on the other hand, require high-quality storage techniques because they are more sensitive to degradation compared to flower and edibles. Marijuana concentrates will begin to degrade quickly when exposed to the elements. This means that storing cannabis concentrates products poorly for even a couple of hours could severely degrade them and cause them to change color to black or brown as well as lose their potency and taste. Given the razor-thin profit margins in the concentrates segment, improper storage could have a significant impact on your bottom line. It is prudent for retailers to know how best to store every kind of marijuana product from different companies such as Cannabis Strategic Ventures, Inc. (OTC: NUGS) because a storage method that is adequate for one product type may be woefully inadequate for another type of product.

Cannabis Strategic Ventures Inc. (OTC: NUGS) is an emerging leader in the U.S. cannabis marketplace as a publicly traded cannabis cultivator. The company is based in Los Angeles, with a 6-acre cannabis farm in Northern California called NUGS Farm North. The company’s vision is to acquire and scale assets in the legal cannabis market while achieving efficiencies through economies of scale and vertical integration.

Cannabis Strategic Ventures recently expanded its portfolio by completing the transfer process for cultivation, retail, distribution and manufacturing licenses issued by the City of Los Angeles and the State of California, and it is now working toward taking operational control of each license. The company also recently announced the upcoming grand opening of its cannabis dispensary, MDRN Tree. Following that launch, Cannabis Strategic Ventures intends to deploy another of its new licenses to establish an indoor cultivation facility with capacity to produce two to three pounds of premium exotic cannabis flower per light per harvest. The facility will have up to 1,200 grow lights and is anticipated to yield 5.75 harvests per year, bringing it to a total production capacity of over 15,000 pounds of cannabis flower annually.

Brand Portfolio

The company owns multiple brands under the Cannabis Strategic Ventures umbrella. The firm’s NUGS brand provides operational and financial strategic partnerships and a range of essential services to emerging and existing cannabis consumer brands.

The NUGS Farm North brand operates as a six-and-a-half-acre cannabis cultivation property located in northern California. The company believes that the key to success in its business is consistent quality and reliable supply to fit growing consumer demand. Cannabis Strategic Ventures addressed these consumer needs by building NUGS Farm North. At NUGS Farm North, the company’s process is customized, and its product is consistent. Located in the heart of an agricultural mecca for globally distributed produce, NUGS Farm North finds power in its product, not in its size. Decades of agricultural experience and a dedication to consistency ensure quality cannabis.

MDRN Tree is Cannabis Strategic Ventures’ customer-facing dispensary brand. MDRN Tree will open its first Los Angeles location sometime in the fall of 2021. MDRN Tree will be the company’s factory retail store – a direct interface with the end-market community – where Cannabis Strategic Ventures plans on showcasing the cannabis flower produced at its NUGS Farm North cultivation site. This farm-to-sale model offers the potential to drive simultaneous gains in quality control and profitability.

Market Outlook

The demand for legal marijuana is expected to surge due to ongoing changes in U.S. state government policies toward cannabis. In addition, the number of indications for which medical marijuana is prescribed continues to increase steadily. These factors are expected to rapidly boost legal sales of cannabis products, opening new revenue channels for producers and retailers. Furthermore, an anticipated federal legalization of medical marijuana in the U.S. will only present more high growth opportunities for this market.

According to a report from Grand View Research, the global legal marijuana market was valued at $9.1 billion in 2020. Market size is forecast to grow at a compound annual growth rate of 26.7 percent from 2021 to 2028. That CAGR would put the market value at roughly $30 billion as soon as 2025.

According to the report, “One of the major factors fueling market growth is the expanding demand for legal marijuana owing to the growing number of legal cannabis countries. (Due) to recent legalizations in different countries, the use of medical marijuana for various ailments is gaining momentum worldwide. Patients suffering from chronic illnesses such as Parkinson’s, cancer, Alzheimer’s, and many neurological disorders are administered medical marijuana. The demand for cannabis oil is increasing rapidly, especially among countries with legalized medical marijuana.”

Management Team

Simon Yu is CEO, President, CFO and Secretary of Cannabis Strategic Ventures. He is also a co-founder, former COO and board member of Clubhouse Media Group Inc., a publicly traded social media company. Mr. Yu holds an MBA from the University of Southern California.

Cannabis Strategic Ventures Inc. (NUGS), closed Tuesday's trading session at $0.0148, off by 3.268%, on 1,648,372 volume. The average volume for the last 3 months is 27,000 and the stock's 52-week low/high is $0.0103/$0.073.

Recent News

The QualityStocks Numbers Report

By The Numbers Chart

Top Performers

The QualityStocks Sponsored News

The QualityStocks DailyNetwork Sponsors

CannabisNewsWireCanadianCannabisNewsWireCNW420CannabisNewsWatchCBDWireCryptoCurrencyWireGot Stocks?Got Stock Tips?Green On The StreetHempWireNewsInvestorOutreachCenterMissionIRMissionIR MediaMissionPR MissionSMRNetworkNewsWireNetworkNewsWatchNetworkWireQualityStocks MediaQualityStocksQualityStocks TwitsSeriousTradersSmallCapRelationsSocial Media RelationsSmallCapSocietyTiny GemsTip.usTraderPower

ActionStockPicksAgressive StocksBetting On Wall StreetGreen Car StocksGreen Energy StocksHomeRunStocksInvestorBrandWireQStocksStock BeatsStockTipsStocks To Buy NowTerrificStocks

About The QualityStocks Daily

The QualityStocks Daily Newsletter brings you the latest company News and Profiles featuring the "Top Movers and Shakers" from the Small Cap Market each trading day. QualityStocks is committed to bring our subscribers Public companies in our Newsletter Section "Free of Charge" based on Percentage gained, Momentum, Press, and or Company Fundamentals.

Why do we spotlight companies for Free?
We Want To bring our subscribers the top movers in an unbiased setting.

"Homework Eliminates Mistakes"
Please never invest in a company anyone profiles unless you do the proper research and due diligence.

QualityStocks is compensated by the companies in The QS Company Corner. These companies will include a disclaimer with the amount and term of compensation.

Please consult the QualityStocks Market Basics Section on our site.

The QualityStocks Numbers Report

By The Numbers Chart

Top Performers


QualityStocksTwits is your stock tracking service portal to Twitter's universe of stock picks, commentary and research.

Visit Portal

The QualityStocks Sponsored News

The QualityStocks DailyNetwork Sponsors

CannabisNewsWireCanadianCannabisNewsWireCNW420CannabisNewsWatchCBDWireCryptoCurrencyWireGot Stocks?Got Stock Tips?Green On The StreetHempWireNewsInvestorOutreachCenterMissionIRMissionIR MediaMissionPR MissionSMRNetworkNewsWireNetworkNewsWatchNetworkWireQualityStocks MediaQualityStocksQualityStocks TwitsSeriousTradersSmallCapRelationsSocial Media RelationsSmallCapSocietyTiny GemsTip.usTraderPower

ActionStockPicksAgressive StocksBetting On Wall StreetGreen Car StocksGreen Energy StocksHomeRunStocksInvestorBrandWireQStocksStock BeatsStockTipsStocks To Buy NowTerrificStocks

About The QualityStocks Daily

The QualityStocks Daily Newsletter brings you the latest company News and Profiles featuring the "Top Movers and Shakers" from the Small Cap Market each trading day. QualityStocks is committed to bring our subscribers Public companies in our Newsletter Section "Free of Charge" based on Percentage gained, Momentum, Press, and or Company Fundamentals.

Why do we spotlight companies for Free?
We Want To bring our subscribers the top movers in an unbiased setting.

"Homework Eliminates Mistakes"
Please never invest in a company anyone profiles unless you do the proper research and due diligence.

QualityStocks is compensated by the companies in The QS Company Corner. These companies will include a disclaimer with the amount and term of compensation.

Please consult the QualityStocks Market Basics Section on our site.

The QualityStocks Numbers Report

By The Numbers Chart

Top Performers


QualityStocksTwits is your stock tracking service portal to Twitter's universe of stock picks, commentary and research.

Visit Portal

The QualityStocks Sponsored News

The QualityStocks DailyNetwork Sponsors

CannabisNewsWireCanadianCannabisNewsWireCNW420CannabisNewsWatchCBDWireCryptoCurrencyWireGot Stocks?Got Stock Tips?Green On The StreetHempWireNewsInvestorOutreachCenterMissionIRMissionIR MediaMissionPR MissionSMRNetworkNewsWireNetworkNewsWatchNetworkWireQualityStocks MediaQualityStocksQualityStocks TwitsSeriousTradersSmallCapRelationsSocial Media RelationsSmallCapSocietyTiny GemsTip.usTraderPower

ActionStockPicksAgressive StocksBetting On Wall StreetGreen Car StocksGreen Energy StocksHomeRunStocksInvestorBrandWireQStocksStock BeatsStockTipsStocks To Buy NowTerrificStocks

About The QualityStocks Daily

The QualityStocks Daily Newsletter brings you the latest company News and Profiles featuring the "Top Movers and Shakers" from the Small Cap Market each trading day. QualityStocks is committed to bring our subscribers Public companies in our Newsletter Section "Free of Charge" based on Percentage gained, Momentum, Press, and or Company Fundamentals.

Why do we spotlight companies for Free?
We Want To bring our subscribers the top movers in an unbiased setting.

"Homework Eliminates Mistakes"
Please never invest in a company anyone profiles unless you do the proper research and due diligence.

QualityStocks is compensated by the companies in The QS Company Corner. These companies will include a disclaimer with the amount and term of compensation.

Please consult the QualityStocks Market Basics Section on our site.